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ABSTRACT 
Protective antiviral immune responses require priming of naïve T cells by 
dendritic cells (DCs) that have matured sufficiently to produce co-stimulatory cell 
surface molecules and cytokines. Although only low levels of productive HIV-1 
infection are detected in ex vivo DCs following HIV-1 challenge, those few cells 
exhibit innate activation. Experimentally bypassing blocks to entry and replication 
leads to more efficient transduction of DCs and maturation as indicated by 
production of interferons and interferon stimulated genes. Furthermore, similar 
innate activation occurs upon transduction of macrophages or CD4+ T cells. 
However, the mechanism by which HIV-1 is detected to activate innate immune 
signaling is not clear. The purpose of this thesis is to incorporate my data and 
observations into the understanding of HIV-1 innate detection and attempt to 
resolve seemingly conflicting observations. 
Reverse transcription and genomic integration are necessary for innate activation 
implying the need de novo transcription. Coding sequences are unnecessary 
save for those cis-acting sequences necessary for the HIV-1 life cycle. CRM1 
dependent, HIV-1 unspliced RNA export is essential for innate activation. As 
intact viral sequence is unnecessary for transcription and export, defective 
proviruses may contribute to systemic inflammation seen in chronically infected 
individuals. These insights, are hoped to aid in the production of qualitatively 
better anti-retroviral drugs as well as in the design a protective HIV vaccine.    
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Introduction  
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1.1  Brief Introduction 
Presently, there are over 40 antiretroviral drug formulations approved by the FDA 
marketed specifically to inhibit HIV-1 replication (FDA.gov).  These drugs are 
designed to obstruct various specific steps of the HIV-1 life cycle including fusion 
and entry, reverse transcription, integration, and HIV-1 protease processing (Arts 
and Hazuda, 2012).  These formulations can be very effective in reducing viral 
load in infected individuals to near-undetectable levels, curtailing the risk of viral 
transmission, and preventing progression to AIDS.  Unfortunately, while 
antiretroviral medications are highly effective in inhibiting the HIV-1 life cycle, 
they are neither a cure nor a protective vaccine.  HIV-1 infected individuals must 
maintain a strict regimen of antiviral drugs or risk viral rebound and drug 
resistance (Davey et al., 1999; Johnson et al., 2013; Siliciano and Siliciano, 
2013; Wang et al., 2011).  Furthermore, it is economically and logistically difficult 
to distribute medication to areas of the world most impacted by HIV-1.  According 
to the most recent data available from UNAIDS, an estimated global 36.7 million 
people were HIV-1 positive with approximately 1.8 million new infections and 1 
million AIDS related deaths in 2016 alone (UNAIDS.org).  This highlights the truth 
that, although modern therapies are incredibly effective in managing HIV, no cure 
exists and more people are infected every year underscoring the critical need for 
a protective vaccine that prevents establishment of infection.  
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1.2  HIV-1 Virology 
Human immunodeficiency virus 1 (HIV-1) is an RNA virus of the genus Lentivirus 
in the family Retroviridae.  HIV-1 is a positively stranded, RNA virus enclosing 
two copies of a single 9.5 kb RNA genome (Wain-Hobson et al., 1985; Watts et 
al., 2009).  Like all retroviruses, HIV-1 encodes a single stranded RNA genome 
that is reverse transcribed to produce a double stranded DNA copy.  This cDNA 
copy is transported to the nucleus where it is incorporated in the host 
chromosomal DNA.  Once integrated, this single genome encodes for 15 viral 
protein products that it produces through complex alternative splicing and 
proteasomal processing.   
Prior to cellular infection, the HIV-1 virion is contained within a lipid bilayer 
composed of host cellular membrane.  Within the viral membrane, the RNA 
genomes are themselves enclosed in a conical structure derived from the viral 
capsid protein (CA) (Ganser et al., 1999; Li et al., 2000).  The CA monomers 
assemble into repeating units of hexamers with critically placed pentamers to 
generate a curvature with conical shape.  This structure, similarly termed as the 
viral capsid, also encloses the viral reverse transcriptase (RT) and integrase (IN) 
enzymes.  HIV-1 infects CD4+ T cells, and to a lesser extent macrophages and 
dendritic cells, through the binding of a trimeric viral Env complex to cell surface 
CD4 and a coreceptor, generally CCR5 or CXCR4 (Arrildt et al., 2012; Munro 
and Mothes, 2015; Pancera et al., 2014).  Following receptor association, Env 
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drives fusion of the viral and cellular membranes leading to release of the of the 
HIV-1 capsid structure into the cytoplasm.   
Following entry, the RNA genome is reverse transcribed by the RT enzyme to a 
single, minus stranded DNA copy (Hu and Hughes, 2012).  In proliferating CD4+ 
T cells, where cytoplasmic dNTP levels are abundant, this reaction occurs 
quickly following entry.  However, in non-dividing cells with limited cytoplasmic 
dNTPs such as DCs and macrophages, reverse transcription proceeds much 
more slowly taking up to 48 hours (Kim et al., 2012).  The RT enzyme also has 
an RNase H subunit which degrades the RNA genome following completion of 
the first complementary DNA (Driscoll et al., 2001).  With the RNA copy removed, 
RT continues to synthesize the plus stranded DNA.  At some point during this 
time, the viral capsid structure dissociates to release the reverse transcription 
complex; although whether this occurs early after entry, during cytoplasmic 
transport, or after nuclear pore complex binding is not well understood (Aiken, 
2006; Campbell and Hope, 2015; Chin et al., 2015; Hulme et al., 2015; Peng et 
al., 2014).  Following nuclear import, the HIV-1 integrase enzyme cleaves the 
host DNA to induce a strand transfer reaction.  Host DNA damage complexes are 
then recruited to repair the lesion thereby completing viral DNA incorporation 
(Craigie and Bushman, 2012; Krishnan and Engelman, 2012; Lesbats et al., 
2016).  
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Once the HIV-1 genome is integrated into the host chromosomal DNA, cellular 
factors including NF-κB, Sp1, TATA box binding protein (TBP), and RNA 
polymerase II (RNA Pol II) bind to the promoter element of the 5’ long terminal 
repeat (LTR) (Nabel and Baltimore, 1987; Rittner et al., 1995; Wei et al., 1998).  
This minimal complex allows for low level transcription of HIV-1 RNAs.  The 
majority of which are short, abortive transcripts that incompletely transcribed and, 
ostensibly, quickly degraded (Kao et al., 1987).  However, a small number 
complete transcription and are subsequently spliced and processed (Das et al., 
2011; Karn and Stoltzfus, 2012).  This early, low level transcription allows for the 
the translation of the viral transactivation factor (Tat).  Tat then binds to the trans-
activation response element (TAR) of the HIV-1 LTR and recruits the positive 
transcriptional elongation factor (P-TEFb) (Dingwall et al., 1989, 1990; Tahirov et 
al., 2010).  This, in turn, phosphorylates RNA Pol II leading to a significant 
enhancement of viral transcription (Bieniasz et al., 1999; Karn and Stoltzfus, 
2012; Richter et al., 2002).  
HIV-1 transcribes and processes its pre-mRNA into over 100 different 
alternatively spliced variants (Ocwieja et al., 2012).  Three separate classes of 
HIV-1 mRNAs result from HIV-1 RNA splicing:  unspliced genomic RNA encoding 
Gag and Gag-Pol polyproteins, partially spliced RNAs encoding Env, Vif, or Vpu, 
and multiply spliced RNA encoding Rev, Tat, Vpr, or Nef (Karn and Stoltzfus, 
2012; Kim et al., 1989; Purcell and Martin, 1993).  Multiply spliced HIV-1 RNAs 
are exported from the nucleus using the canonical NXF1/TAP mRNA export 
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pathway.  In contrast, partially spliced and full length HIV-1 RNAs retain the 
major Env intron and are blocked from export (Cullen, 2003; Jensen et al., 2003; 
Rekosh and Hammarskjold, 2018; Sommer and Nehrbass, 2005; Stutz and 
Izaurralde, 2003).  The HIV-1 protein Rev potentiates nuclear export of these 
RNAs by associating with the Rev response element (RRE), contained within the 
Env intron, and binding to the karyopherin CRM1 which drives export outside of 
the NXF1/TAP pathway (Cochrane et al., 1990; Cullen, 2003; Emerman et al., 
1989; Fischer et al., 1995; Malim et al., 1989; Rojas-Araya et al., 2015).    
Once exported from the nucleus, full length, unspliced HIV-1 RNA is translated 
into the Gag and Gag-Pol polyproteins.  An RNA motif of “slippery sequence” 
(UUUUUUA) along with an upstream ACAA tetraloop induces a -1 ribosomal 
frameshift in around 5 percent of the translating molecules thereby producing 
Gag-Pol from the same RNA transcript (Bell and Lever, 2013; Biswas et al., 
2004; Dulude et al., 2002; Mouzakis et al., 2013; Staple and Butcher, 2005).  The 
Gag and Gag-Pol polyproteins then associate with a small number of membrane 
bound Env trimers upon the inside surface of the host cell membrane along with 
two copies of the unspliced HIV-1 RNA genome (D’Souza and Summers, 2005; 
Sundquist and Kräusslich, 2012).  Gag protein is sufficient to drive viral budding 
from the cell membrane; however, it utilizes the host ESCRT pathway to 
potentiate viral release (Bieniasz, 2006, 2009; Carlton and Martin-Serrano, 2007; 
Göttlinger et al., 1991; von Schwedler et al., 2003; Usami et al., 2009; Votteler 
and Sundquist, 2013; Weiss and Göttlinger, 2011).  Once released from the cell 
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membrane, the viral particle exists as a membrane bound, spherical array of 
outwardly facing Gag and Gag-Pol molecules.  The viral protease enzyme (PR), 
itself autocatalytically processed from the Gag-Pol molecule, subsequently 
cleaves the Gag and Gag-Pol into its constituent elements, matrix (MA), capsid 
(CA), nucleocapsid (NC), p6, protease (PR), reverse transcriptase (RT), and 
integrase (IN).  The viral MA proteins remain associated to the membrane 
forming a discontinuous layer.  Inside, the CA monomers spontaneously 
assemble into the conical structure of the mature virion and enclose the genomic 
RNA (Ganser et al., 1999; Sundquist and Kräusslich, 2012; Zhao et al., 2013).  
At this point, the matured viral particle is infectious and ready to restart the cycle.    
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Figure  1.1 
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Figure  1.1  Depiction of the HIV-1 viral life cycle 
I. The HIV-1 virion is contained within a lipid bilayer composed of host cellular 
membrane.  Within the viral membrane, the RNA genomes are themselves 
enclosed in the viral capsid protein which also encloses the viral reverse 
transcriptase (RT) and integrase (IN) enzymes (Campbell and Hope, 2015).  II. 
Viral entry is potentiated by Env interactions with CD4 and a coreceptor, 
generally CCR5 or CXCR4 (Arrildt et al., 2012; Munro and Mothes, 2015).  III. 
Following entry, the viral capsid is released into the cytoplasm.  IV. Reverse 
transcription of the viral RNA genome to cDNA occurs during cytoplasmic 
transport (Hu and Hughes, 2012).  During transport, the viral capsid dissociates 
at an unknown rate (Campbell and Hope, 2015). V. Following reverse 
transcription, viral cDNA is transported to the nucleus.  VI. The viral cDNA is 
transported to the nucleus where it is incorporated into host chromosomal DNA 
by integrase (Craigie and Bushman, 2012; Lesbats et al., 2016).  Here, viral RNA 
is transcribed by host factors following transactivation by Tat (Karn and Stoltzfus, 
2012)  VII. Fully spliced viral RNAs are exported from the nucleus by the 
canonical TAP/NXF1 mRNA export pathway.  However, partially or unspliced 
viral HIV-1 RNAs are exported through the CRM1 export pathway (Cullen, 2003; 
Pocock et al., 2016).  VIII. Unspliced HIV-1 RNA translates the Gag and Gag-Pol 
polyproteins which assemble at the cell membrane and promote viral budding 
(Bell and Lever, 2013; Sundquist and Kräusslich, 2012).  IX. Following Gag 
assembly, viral membrane fission is driven by the host ESCRT complex (Usami 
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et al., 2009; Votteler and Sundquist, 2013).  The viral protease enzyme then 
cleaves the Gag and Gag-Pol polyproteins into their functional constituents and 
the capsid protein auto-assembles into the viral capsid hexagon lattice enclosing 
the viral RNA (Bell and Lever, 2013).   
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1.3  HIV-1 Persistence  
The majority of those infected with HIV-1 mount an antigen-specific immune 
response against the virus with antibodies as well as CD4+ and CD8+ responses 
(Altfeld et al., 2002; Cao et al., 2003; Rosenberg et al., 1997; Scheid et al., 2009; 
Virgin and Walker, 2010).  These immune responses are of varying effectiveness 
but will generally reduce viremia by logs, largely correlating with HIV-1-specific 
CD8+ T cell responses.  However, those infected with HIV-1 progress to AIDS 
despite having measurable antiviral immune responses of varying efficacy.  The 
important exception are the small percentage of individuals referred to as elite 
controllers who can constrain HIV-1 replication and resist progression to AIDS; 
although the exact reason for their resistance is unknown (Bello et al., 2009; 
Fowke et al., 1996; Porichis and Kaufmann, 2011; Saag and Deeks, 2010; 
Walker, 2007).  As stated though, the majority of HIV-1 infected patients, without 
consistent access to antiretroviral medication, will progress to AIDS.  The reason 
for the resistance to viral elimination has been the subject of intense research 
with the expectation that a better understanding of how HIV-1 evades immune 
control will lead to the design of a better antiviral therapies or a prophylactic 
vaccine.  A simple, intuitive explanation is the simple fact that HIV-1 infects and 
inactivates the same CD4+ T cells tasked with antiviral defense.  However, the 
ability to infect and replicate in immune cells is not unique to HIV-1.  
Furthermore, anti-HIV-1 cellular and humoral responses are readily detectable 
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prior to immune collapse and establishment of AIDS, indicating that CD4+ T cell 
activity is not wholly functionally impaired.   
The HIV-1 Env glycoprotein is the only extracellular viral protein and is therefore 
uniquely exposed to antibody attack.  In response, Env has evolved a closed 
conformational state that encloses and conceals receptor binding interfaces and 
functional centers.  Furthermore, the Env protein is covered in an extensive 
glycan “shield” that occludes antibody access.  Indeed, this glycan layer makes 
up half of Env’s total molecular weight (Julien et al., 2013; Lyumkis et al., 2013; 
Munro and Mothes, 2015; Pancera et al., 2014).  HIV-1’s capacity for mutation 
and functional plasticity is another oft-cited basis for HIV-1 persistence.  Indeed, 
HIV-1 has great capacity for mutation and immunological escape due largely to 
the error-prone reverse transcriptase enzyme (Abram et al., 2010; Bowman et 
al., 1998; Hu and Hughes, 2012; O’Neil et al., 2002).  In particular, Env protein is 
capable of tremendous sequence and conformation divergence while still 
maintaining its function (Moore et al., 2012; Powell et al., 2017; Richman et al., 
2003; Wei et al., 2003).  However, high rates of mutation and co-infection of 
sequence variants referred to as quasispecies are common among RNA viruses 
and, alone, cannot account for the failure of the immune system to lastingly 
control HIV-1 infection (Andino and Domingo, 2015; Lauring and Andino, 2010).   
Another important point is that, like all retroviruses, HIV-1 creates a DNA copy of 
its RNA genome and integrates its own sequence into the host cell's 
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chromosomal DNA.   At which point, regardless of its ability to replicate, HIV-1 
becomes a permanent genetic element of the infected cell and all its daughter 
cells.  The provirus may exist in a transcriptionally active state thereby 
contributing to the active infection.  On the other hand, the provirus may, for 
reasons not well understood, become transcriptionally silenced.  In this way, the 
virus creates a pool of infected cells harboring inactive proviruses that can go 
undetected by the immune system (Finzi et al., 1999; Hiener et al., 2017; Lorenzi 
et al., 2016; Mbonye and Karn, 2017; Siliciano et al., 2003).  This latent reservoir 
of infected cells can persist despite effective immune control or antiretroviral 
therapy.  Transcriptional reactivation of latently infected cells can then re-
establish viral production upon halting of therapy or immune exhaustion.   
The latent reservoir of HIV-1 infected cells is considered to be the major barrier 
obstructing viral eradication.  Histone deacetylases, transcriptional activators, 
and other latency reversal agents have been used both in vitro and clinically to 
reactivate latent viral reservoirs in the hopes of promoting immune clearance of 
infected cells.  However, in vitro, ex vivo, and humanized mice experiments have 
shown that HIV-1 specific cytotoxic T lymphocytes (CTL) fail to eliminate latently 
infected CD4+ T cell upon transcriptional reactivation unless the CTL are 
secondarily stimulated (Deng et al., 2015; Huang et al., 2018; Shan et al., 2012; 
Smith et al., 2016; Spina et al., 2013).  This would suggest that the existing 
immune response to HIV-1 infection is in some way deficient.  Indeed, a long 
body of evidence indicates that HIV-1 alters T cell function beyond simply 
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depleting them via infection.  Chronic HIV-1 infection induces both CD4+ and 
CD8+ T cells to have an “exhausted” phenotype characterized by the expression 
of inhibitory receptors and of reduced effector function and cytokine 
responsiveness.  The exact cause of T cell exhaustion is unknown but is known 
to result from repeated antigen stimulation and inflammation as occurs in chronic 
HIV-1 infection (Amu et al., 2016; Blackburn et al., 2009; Buggert et al., 2014; 
Day et al., 2006; Douek et al., 2003; Larsson et al., 2013; Morou et al., 2014; 
Wherry and Kurachi, 2015; Yamamoto et al., 2011; Zajac et al., 1998).   
 
1.4  HIV-1 interactions with DCs 
A functional adaptive immune response depends on proper communication of 
pathogenic antigens to T cells by antigen presenting cells. The defective immune 
response to HIV-1 infection may be due to insufficient priming of the adaptive 
immune system.  Dendritic cells (DCs) are a class of highly heterogeneous 
immune cells tasked with the classification and presentation of antigen to T cells.  
The specific activation state of the DCs determines the nature and constitution of 
the immune response elicited by the T cells upon antigen recognition.  Self 
antigen is presented in an inactivated context leading to a tolerogenic immune 
state.  In contrast, DCs present pathogenic antigens in a matured stated leading 
to protective immunity.  Dendritic cells mature upon innate immune recognition of 
danger associated signals (pathogen associated molecular patterns - PAMPs) by 
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an array of highly specific pathogen recognition receptors (PRRs).  Upon PRR 
activation, DCs express costimulatory molecules such as CD80 and CD86 as 
well as secrete numerous cytokines that communicate the nature of the 
presented antigen to T cells.   
As intracellular parasites, virus do not produce completely foreign molecules 
which would readily distinguish them from the host.  As a result, cells often sense 
infection through the detection of viral nucleic acids by a broad array of PRRs.  
Innate detection of viral infection generally leads the induction of type 1 interferon 
(IFN) production as well a large number of interferon stimulated genes (ISG) that 
elicit extensive antiviral activities.  The type 1 IFN response leads to DC 
maturation and is critical to the generation of an antiviral immune response.  
Circulating plasmacytoid dendritic cells (pDCs) readily endocytose HIV-1 
particles and detect HIV-1 RNA via TLR7 and produce copious levels of type I 
interferon (Beignon et al., 2005; Fonteneau et al., 2004; Lepelley et al., 2011; 
O’Brien et al., 2013).  However, pDCs have limited capacity to stimulate antigen 
specific T cells (Boasso et al., 2011; Hoeffel et al., 2007; Jaehn et al., 2008).   
In contrast, myeloid dendritic cells (mDCs) constitute the body’s primary antigen 
presenting cells and lack expression of TLR7 precluding maturation in response 
to HIV-1 (Izaguirre et al., 2003; Miller and Bhardwaj, 2013; O’Brien et al., 2013; 
Smed-Sörensen et al., 2004, 2005).  Myeloid dendritic cells are refractory to 
productive HIV-1 infection with blocks to both entry and reverse transcription.  
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Infection of a cell by HIV-1 requires binding of cell surface CD4 and CCR5 with 
the HIV-1 Env glycoprotein complex.  This initiates a fusion event that delivers 
the viral capsid core into the cytoplasm.  Surface expression of CD4 on mDCs is 
prohibitively low and viral endocytosis is driven by alternative interactions with 
DC-SIGN and other c-type lectins (Chauveau et al., 2017; Granelli-Piperno et al., 
2004, 2006; Piguet and Steinman, 2007).  Alternatively, viral particles can be 
captured by surface CD169 and transferred to CD4+ T cells, further potentiating 
infection (Cameron et al., 1992; Izquierdo-Useros et al., 2012, 2014; Kijewski and 
Gummuluru, 2015; Piguet and Steinman, 2007).  However, immature DCs are 
more likely to capture HIV-1 via c-type lectins to be endocytosed (Geijtenbeek et 
al., 2000; Kijewski and Gummuluru, 2015; Piguet and Steinman, 2007; Puryear 
et al., 2013; Turville et al., 2002).  In endosomal compartments, HIV-1 is unable 
to reverse transcribe and is rapidly degraded.  Viral antigens are then processed 
and presented in the absence of PRR stimulation and DC maturation (Moris et 
al., 2006).  Paradoxically, this may lead to a more tolerogenic immune response 
with limited antiviral activity.  Indeed, it is well documented that HIV-1 specific T 
cell express inhibitory molecules such as PD-1 and TRAIL  (Brown et al., 2010; 
Day et al., 2006; Khaitan and Unutmaz, 2011; Morou et al., 2014; Trautmann et 
al., 2006; Wherry and Kurachi, 2015).   
The entry block to infection in DCs can be experimentally circumvented when 
HIV-1 virions are pseudotyped with the glycoprotein of a heterologous virus; most 
often Vesicular Stomatitis Virus glycoprotein (VSV-G) (Granelli-Piperno et al., 
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2000).  This allows for the productive release of the HIV-1 capsid into the 
cytoplasm.  However, DCs and other non-dividing myeloid cells contain another 
block to productive infection.  The host dNTP nuclease SAMHD1 restricts 
reverse transcription in dendritic cells possibly due to depletion of cytoplasmic 
dNTPs (Goldstone et al., 2011; Lahouassa et al., 2012; Powell et al., 2011) or by 
an as yet unknown, nuclease independent mechanism (Lim et al., 2012; 
Reinhard et al., 2014; White et al., 2013).  The HIV-2 and SIV specific protein 
Vpx has been found to rescue this block to infection by promoting the 
proteasomal degradation of SAMHD1 following CUL4A ubiquitination by direct 
binding of DCAF1 (Bergamaschi et al., 2009; Hrecka et al., 2011; Sharova et al., 
2008; Srivastava et al., 2008).  When provided in trans via  SIVMAC251 viral-like 
particles (SIV VLPs) the Vpx protein is able to fully facilitate HIV-1 reverse 
transcription in DCs (Goujon et al., 2006; Laguette et al., 2011; Nègre et al., 
2000).  
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Figure 1.2   
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Figure  1.2  HIV-1 transduction of dendritic cells 
Dendritic cells are differentiated in vitro following the positive selection of CD14+ 
monocytes.  CD14+ cells are plated at a density of 1 to 2 x 106 cells/ml in RPMI-
1640 supplemented with 5% heat inactivated human AB+ serum, 20 mM L-
glutamine, 25 mM HEPES pH 7.2, 1 mM sodium pyruvate, and 1x MEM non-
essential amino acids (RPMI-HS complete). DCs were generated by culturing 
monocytes for 6 days in the presence of 1:100 cytokine-conditioned media 
containing human GM-CSF and human IL-4 (McCauley et al., 2017; Pertel et al., 
2011). 
Depicted are SIV viral like particles (VLPs) that are produced to deliver Vpx 
protein which enhances reverse transcription by depleting host SAMHD1.  Both 
the SIV VLPs and the HIV-1 or lentivector are pseudotyped with VSV-
glycoprotein to potentiate CD4 independent entry.  Dendritic cells do not detect 
infection from minimal lentivectors and genes can be delivered (GFP) without 
stimulating the cells (McCauley et al., 2017).  However, full length HIV-1 infection 
does lead to the maturation of DCs as evident by the long extensions spreading 
outward from the cell body.    
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1.5  HIV-1 Incoming  
The innate immune response to HIV-1 infection has been widely disputed among 
different labs with greatly varying results.  Several groups have failed to detect 
innate detection in myeloid dendritic cells even under conditions where HIV-1 
transduction is optimized using VSV-G pseudotyped virus supplemented with 
Vpx-containing SIV VLPs (Beignon et al., 2005; Fonteneau et al., 2004; Granelli-
Piperno et al., 2004; Smed-Sörensen et al., 2005).  In contrast, a growing body of 
evidence suggests that, depending on the experimental system used, HIV-1 
infection can be detected by DCs.  For example, a common route of viral 
detection is through the sensing of unique nucleic acid forms and locations.   
Multiple cellular receptors have been shown to detect RNA in a range of viral 
infections.  Endosomal toll-like receptors (TLR) including TLR3, TLR7, and TLR8, 
as well as cytoplasmic RIG-I like receptors (RLRs) have been well characterized 
to sense diverse forms of single and double stranded viral RNA (Brencicova and 
Diebold, 2013; Iwasaki and Medzhitov, 2010; Thompson et al., 2011).  As a 
positive sense, single stranded RNA virus with extensive secondary structure, 
HIV-1 may be exposed to detection from several RNA sensors.  As previously 
mentioned, HIV-1 is readily endocytosed by plasmacytoid dendritic cells (pDC) 
where its genomic RNA is detected by TLR7.  The main result of which is the 
production of impressive quantities of IFNα (Beignon et al., 2005; Fonteneau et 
al., 2004; Haupt et al., 2008; Lepelley et al., 2011; O’Brien et al., 2013; Smed-
 
 
21 
 
 
Sörensen et al., 2005).  However, pDCs have limited capacity to present antigen 
to T cells and may in fact express inhibitory factors that limit the antiviral T cell 
response (Boasso et al., 2007, 2011; Hoeffel et al., 2007; Jaehn et al., 2008; 
Manches et al., 2008).   In contrast to pDCs, myeloid dendritic cells have limited 
expression of TLR7 and IRF7 (essential for TLR7 signaling) and do not detect 
HIV-1 in the same manner (Bloch et al., 2014; Izaguirre et al., 2003; Jarrossay et 
al., 2001; Kaisho, 2012; Smed-Sörensen et al., 2005; Wacleche et al., 2018).     
Methods of HIV-1 RNA detection by other cellular receptors have been 
suggested.  Although mDCs are impeded in TLR7 RNA detection, TLR8 
signaling appears to be intact and has been suggested to detect incoming HIV-1 
RNA (Gringhuis et al., 2010).  In this study, sensing of HIV-1 RNA by TLR8 was 
shown to activate NF-κB and acted to enhance transcription of the integrated 
HIV-1 genome.  However, neither DC maturation nor a type 1 interferon 
response was reported following infection.  RIG-I is a cytoplasmic RNA sensor 
that detects 5’ triphosphorylated RNAs as well as RNAs with short double 
stranded motifs (Reikine et al., 2014).  The complex and highly regulated 
secondary structure of HIV-1 genomic RNA has been implicated as a substrate 
for RIG-I signaling in cell lines and human PBMCs (Berg et al., 2012; Solis et al., 
2011).  However, these experiments were completed through transfection of 
various HIV-1 derived RNA motifs as opposed to direct HIV-1 challenge.  As 
such, the relevance of these observations to true HIV-1 challenge or in cells 
types like DCs is still unknown. 
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The TREX1 protein is a cytosolic DNA nuclease has been reported to degrade 
cytoplasmic HIV-1 cDNA following reverse transcription of the RNA genome (Yan 
et al., 2010).  Depletion of TREX1 protein resulted in the accumulation of excess 
reverse transcribed viral cDNA leading to the activation of an unknown 
cytoplasmic DNA sensor.  Supporting this model, TREX1 knockdown was shown 
to inhibit HIV-1 infection in vitro and in humanized mice through the induction of 
an antiviral interferon response (Wheeler et al., 2016).  Furthermore, in a THP1 
model of HIV-1 infection, innate activation was shown to be dependent on the 
expression level of TREX1 as due to its degradation of partial reverse 
transcription products (Kumar et al., 2018).  
The resultant detection of reverse transcribed viral cDNA in dendritic cells was 
argued to be mediated by the cytoplasmic DNA sensor, cyclic GMP-AMP 
synthase (cGAS) (Gao et al., 2013; Wu et al., 2013).  Double stranded DNA or 
single stranded DNA with Y-form secondary structure activates the cGAS 
enzyme to produce the secondary messenger cGAMP (cyclic GMP-AMP) to 
activate STING and, consequently, IFN via IRF3 (Chen et al., 2016; Herzner et 
al., 2015; Yoh et al., 2015).  HIV-1 transduction led to cGAMP production and 
IRF3 dimerization in monocyte derived dendritic cells and macrophages only 
when reverse transcription was facilitated through the addition of Vpx (Gao et al., 
2013).  In similar experiments, polyglutamine binding protein 1 (PQBP1) was also 
found to directly bind HIV-1 cDNA (Yoh et al., 2015).  This interaction led to a 
type 1 interferon response that was dependent on cGAS; implying a model where 
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the specific binding capacity of retroviral cDNA is modulated by interactions with 
both cGAS and PQBP1 as a complex.   
In another study, HIV-1 cDNA was found not to be sensed by DCs even upon 
depletion of SAMHD1 by Vpx.  Mutation of the HIV-1 capsid protein (CA) to 
increase affinity for the cytoplasmic protein cyclophilin A (CypA) led to detection 
and DC maturation (Lahaye et al., 2013).  CypA binds to the HIV-1 capsid 
structure following viral entry and leads to stabilization of the capsid structure and 
regulation of capsid disassembly (De Iaco and Luban, 2014; Franke et al., 1994; 
Li et al., 2009; Luban et al., 1993; Sokolskaja et al., 2006; Thali et al., 1994).  
Sheltered in the capsid structure, viral cDNA is ostensibly protected from cGAS 
detection.  Increasing the CA affinity to CypA was suggested to lead to 
premature capsid uncoating thereby leaving the HIV-1 cDNA exposed prior to 
nuclear entry (Lahaye et al., 2013; Maelfait et al., 2014).   
In partial agreement with this model, HIV-1 was reported to circumvent innate 
detection in monocyte derived macrophages through CA interactions with both 
CypA and CPSF6 (Rasaiyaah et al., 2013).  CPSF6, an mRNA polyadenylation 
factor, associates with CA to facilitate HIV-1 nuclear import through association 
with the importin TNPO3 (Brass et al., 2008; De Iaco et al., 2013; Price et al., 
2012; Valle-Casuso et al., 2012).  Mutations blocking these interactions inhibited 
HIV-1 infection through the induction of type 1 interferon following production of 
cGAMP, thereby implicating cGAS detection of cDNA (Rasaiyaah et al., 2013).  
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However, this interaction did not depend on Vpx promotion of reverse 
transcription, possibly due to differential restriction of reverse transcription by 
SAMHD1 in macrophages (Cribier et al., 2013; White et al., 2013).  Furthermore, 
innate detection of HIV-1 was proposed to be promoted by reduction of CypA-CA 
binding as opposed to increased binding as suggested in DCs.    
IFI16, another cellular DNA sensor, has also been shown to detect transfected, 
HIV-1 based DNA sequences and induce type 1 interferon in macrophages 
(Jakobsen et al., 2013).  Similarly, IFI16 was implicated to sense products of 
incomplete reverse transcription in resting CD4+ T cells isolated from tonsil 
explants (Monroe et al., 2014).  This led to caspase 1 activation, induction of the 
IL1β inflammasome, and consequently, bystander T cell death as due to 
pyroptosis (Doitsh et al., 2010).  As CD4+ T cells constitute the primary target of 
HIV-1 replication, the observation that IFI16 may also detect HIV-1 cDNA and 
lead to indirect T cell depletion is of considerable interest.  However, an 
analogous mechanism of IFI16 has not been observed in specialized antigen 
presenting such as dendritic cells and macrophages.  Similarly to the role of 
PQBP1 in modulating cGAS activity, IFI16 has also been suggested to function 
as a cofactor in cGAS recognition of HIV-1 reverse transcription products 
(Jønsson et al., 2017).  In this study, knockdown of IFI16 led to decreased 
production cGAMP and attenuated the cGAS-STING dependent innate immune 
response to Vpx-assisted HIV-1 infection in macrophages.  This supports a 
cGAS detection model in which retroviral cDNA is detected in the cytoplasm by 
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cGAS with proteins including PQBP1 and IFI16 acting to enhance retroviral DNA 
binding and enzymatic activity (Jønsson et al., 2017; Sumner et al., 2017).     
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Figure 1.3   
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Figure 1.3  Detection of intracellular viral cDNA 
I.  The HIV-1 capsid complex may not sufficiently disassemble enough prior to 
nuclear transport to allow cytoplasmic DNA sensors access to viral cDNA, 
thereby bypassing cytoplasmic detection (Lahaye et al., 2013; Maelfait et al., 
2014; Rasaiyaah et al., 2013).  II.  The viral capsid may also uncoat sufficiently 
prior to nuclear entry and allow cytoplasmic access (Campbell and Hope, 2015)  
III.  Once open to the cytoplasm, viral cDNA may be degraded by the nuclease 
TREX1 (Kumar et al., 2018; Wheeler et al., 2016; Yan et al., 2010)  IV.  Cellular 
detection of HIV-1 reverse transcribed cDNA is likely driven by cyclic GMP-AMP 
synthase (cGAS) (Chen et al., 2016; Gao et al., 2013; Herzner et al., 2015; 
Lahaye et al., 2013).  Although other factors such as polyglutamine binding 
protein 1 (PQBP1) and interferon-γ inducible protein 16 (IFI16) may also bind 
HIV-1 cDNA and act to enhance cGAS activity (Jakobsen et al., 2013; Jønsson 
et al., 2017; Yoh et al., 2015).  Following detection, cGAS produces cyclic GAMP 
which activates ER bound stimulator of interferon genes (STING) which 
stimulates TBK1 to phosphorylate IRF3.  Phosphorylated IRF3 then dimerizes 
and transports to the nucleus to drive type 1 interferon expression (Chen et al., 
2016). 
  
 
 
28 
 
 
1.5  Detection of HIV-1 Post Integration 
Sensing of reverse transcription products, be they ssDNA, dsDNA, or RNA-DNA 
hybrids, are events that intuitively would occur prior to HIV-1 genomic integration.  
Rather than detection of products of HIV-1 reverse transcription prior to 
incorporation into the host chromosomal DNA, evidence exists for mechanisms 
of detection dependent on viral integration and transcription.  However, as with 
pre-integration sensing, these studies vary considerably in reported determinants 
and mechanism of innate activation.   
The act of integration itself is a process that requires the insertion of a copy of 
foreign DNA into host chromosomal DNA.  The viral pre-integration complex 
(PIC) associates with LEDGF/p75 to target integration site selection to 
chromosomal locations of high transcriptional activity (Ciuffi et al., 2005; Marshall 
et al., 2007; Shun et al., 2007).  The enzymatic operation consists of the HIV-1 
integrase enzyme cleaving target DNA phosphodiester bonds to induce a strand 
transfer reaction.  A diverse number of host DNA damage complexes are then 
recruited to repair the lesion (Craigie and Bushman, 2012; Lesbats et al., 2016).  
The commissioning of DNA-dependent protein kinase (DNA-PK), an important 
enzymatic and signaling regulator of the non-homologous end joining DNA repair 
pathway, has also been suggested to induce innate immune activation in CD4+ T 
cells (Cooper et al., 2013).  In this study, in vitro HIV-1 infection of cell lines and 
PBMCs led to acute CD4+ T cell death that was found to be dependent on 
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integration.  Signaling of DNA damage by DNA-PK prompted p53 activation and 
induction of cell death.  However, this mechanism of detection has not been 
identified in other cells types such as dendritic cells and still requires independent 
verification. 
Following integration, HIV-1 transcribes its RNA in multiple forms through 
intricate alternative splicing through a complex process of internal regulation.  In 
this way, HIV-1 is able to produce 15 different protein products from only a single 
9 kb pre-mRNA genome (Karn and Stoltzfus, 2012; Stoltzfus and Madsen, 2006).  
The main product of unspliced, genomic HIV-1 RNA is the structural polyprotein 
Gag.  In dendritic cells, produced Gag itself has been suggested to be directly 
detected by the innate immune system (Manel et al., 2010).  In this study, HIV-1 
transduction of dendritic cells induced maturation and a type 1 interferon 
response.  This response was dependent on both Vpx facilitation of reverse 
transcription and on productive integration.  Binding of CypA to capsid, contained 
within de novo synthesized Gag polyprotein, induced an IRF3 dependent type 1 
interferon response through an unknown signaling mechanism.  However, more 
recent work by this group has instead pursued cGAS detection of pre-integrated 
viral cDNA as a primary mechanism for the innate activation seen in DCs  
following optimized HIV-1 challenge (Lahaye et al., 2013; Silvin and Manel, 
2015).   
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Counterintuitively, cGAS detection of HIV-1 infection has also been suggested to 
be dependent on prior integration (Vermeire et al., 2016).  In this study, HIV-1 
infection of IL2/PHA activated CD4+ T cells induced the production of type 1 
interferon that was inhibited upon blocking of either viral integration or 
transcription.  Knockdown of cGAS or its downstream effectors STING or IRF3 
abrogated interferon or ISG production.  Although the authors argue that de novo 
Vpr and Vpu respectively act to potentiate or suppress the antiviral response, a 
mechanism of cytoplasmic DNA sensing by cGAS following HIV-1 proviral 
integration is not elucidated.  Furthermore, even though experiments verifying 
interferon induction and Vpu and Vpr interactions were corroborated in DCs, post 
integration cGAS sensing is not described in cells other than CD4+ T cells 
(Vermeire et al., 2016).   
A recent promontory study has proposed a mechanism of innate detection of 
HIV-1 in dendritic cells involving determinants both before and after viral 
integration (Johnson et al., 2018).  Infection of DCs with a myeloid tropic HIV-1, 
in the presence of Vpx, induced robust DC maturation as evident by CD86 and 
type 1 interferon expression.  Inhibition of HIV-1 integration either with 
Raltegravir or an integrase deactivating mutation, D116, greatly reduced, but did 
not abolish, the innate response to Vpx-assisted HIV-1 challenge.  Secondary 
stimulation of DCs with R848, a TLR7/8 agonist and activator of NF-κB, was 
shown to rescue high level interferon expression in integration deficient 
infections.  Knockdowns in monocyte derived dendritic cells, or CRISPR 
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knockouts in THP1 derived DCs, of the cGAS-STING-IRF3 pathway all reduced 
maturation and ISG expression.  Importantly, disruptions of IFI16, MAVS, PKR, 
IRF1, IRF5, IRF7, or IRF9 had no effect on sensing of HIV-1 whether or not viral 
integration was inhibited (Johnson et al., 2018).  The authors conclude a complex 
model in which cGAS detection of HIV-1 reverse transcription products “primes” 
a low-level type 1 interferon response which, following integration and 
transcription, is amplified by activation of NF-κB. However, neither the 
determinant by which integration and viral production is sensed nor the 
mechanism for the resultant NF-κB activation is determined by this study.  
However, this remains an intriguing hypothesis that may serve to clarify many of 
the seeming conflicting observations reported for HIV-1 innate detection.   
 
1.6  Sensing of HIV-1 RNA Processing 
Following integration, HIV-1 transcribes its RNA and processes it through 
complex alternative splicing and differential export.  HIV-1 processes its pre-
mRNA into over 100 different alternatively spliced variants (Ocwieja et al., 2012).   
As described previously, HIV-1 RNA motifs have been suggested to be 
substrates for the cytoplasmic RNA receptor RIG-I (Berg et al., 2012; Solis et al., 
2011).  The implications for these studies suggest that incoming HIV-1 genomic 
RNA may be innately detected prior to reverse transcription or integration.  
However, these studies are limited mainly to RNA transfections in cell lines and 
 
 
32 
 
 
would be unable to distinguish whether de novo HIV-1 RNAs, as opposed to 
incoming virion associated genomic RNA, could be detected.  One study has 
described a mechanism in which newly transcribed HIV-1 RNA is sensed by the 
host helicase DDX3 (Gringhuis et al., 2016).  In this study, DDX3 was found to 
detect abortive HIV-1 RNA transcripts in a manner dependent on HIV-1 
integration.  Dendritic cell transfection of short HIV-1 RNAs, found in abortive, Tat 
independent transcription, led to type 1 interferon induction in a manner 
dependent on both DDX3 and MAVS.  Knockdowns of DDX3 and MAVS in DCs 
similarly inhibited maturation upon challenge with myeloid tropic HIV-1; however, 
it is unknown whether abortive transcription products constitute the determinant 
for detection in primary cell infection.   
Transcription of the integrated HIV-1 genome follows the binding of cellular 
factors including NF-κB, Sp1, TATA box binding protein (TBP), and RNA 
polymerase II (RNA Pol II) to the promoter element of the 5’ long terminal repeat 
(LTR).  This minimal complex allows for the transcription of a low level of viral 
transcripts, which subsequently undergo splicing and processing (Das et al., 
2011; Karn and Stoltzfus, 2012; Nabel and Baltimore, 1987; Rittner et al., 1995; 
Tahirov et al., 2010). Binding of Tat recruits the positive transcriptional elongation 
factor (P-TEFb) which phosphorylates RNA Pol II leading to a significant 
enhancement of HIV-1 transcription.   
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Three classes of HIV-1 mRNAs result from HIV-1 RNA transcription and splicing:  
unspliced genome RNA encoding Gag and Gag-Pol polyproteins, partially spliced 
RNAs producing Env, Vif, or Vpu, and multiply spliced RNA for synthesis of Rev, 
Tat, Vpr, or Nef (Karn and Stoltzfus, 2012; Pan et al., 2008; Purcell and Martin, 
1993; Schwartz et al., 1990; Stoltzfus, 2009).  Multiply spliced HIV-1 RNAs are 
exported from the nucleus using the canonical NXF1 mRNA export pathway.  In 
contrast, partially spliced and full length HIV-1 RNA retain the major Env intron 
and are restrained to the nucleus due to the formation of splicing complexes 
(Jensen et al., 2003; Sommer and Nehrbass, 2005; Stutz and Izaurralde, 2003).  
Other retroviruses bypass this restriction by encoding constitutive transport 
elements (CTE) that directly bind NXF1 to potentiate export (Aibara et al., 2015; 
Cullen, 2003; Pilkington et al., 2014; Pocock et al., 2016; Rekosh and 
Hammarskjold, 2018).  While experiments have shown that CTE elements are 
sufficient to support HIV-1 RNA export, HIV-1 naturally uses an alternative export 
pathway (Bray et al., 1994; Smulevitch et al., 2006; Valentin et al., 1997).  The 
HIV-1 protein Rev, itself produced from an early, fully spliced transcript, binds to 
and multimerizes upon the Rev response element (RRE) contained within the 
Env intron.  In turn, Rev binds to the karyopherin CRM1 to potentiate nuclear 
export, sans completion of splicing (Cullen, 2003; Nakielny and Dreyfuss, 1999).    
The specialized export of intron containing RNAs is a mechanism not normally 
utilized in mammalian cells and could potentially be sensed as a danger signal.  
Indeed, Rev mediated export of intron containing RNA has been shown to induce 
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innate activation in DCs, macrophages, and CD4+ T cells (Akiyama et al., 2017; 
McCauley et al., 2017).  Challenge with HIV-1 was shown to induce a type 1 
interferon response that was unreliant on cGAS-IRF3 signaling in both DCs 
(McCauley et al., 2017) and macrophages (Akiyama et al., 2017).   This 
response was shown to be dependent upon integration and transcription of the 
provirus.  Furthermore, mutations or deletions of HIV-1 coding sequence failed to 
limit ISG induction suggesting a lack of sequence necessity.  Importantly, while 
VSV-G pseudotyping and Vpx addition enhanced infectivity and innate activation, 
both were unnecessary to induce DC maturation in infected cells.  
Maturation of DCs was still observed upon replacement of Tat mediated 
transcriptional transactivation for a doxycycline inducible HIV-1 (Tet-HIV-1) 
construct.  Innate activation was seen upon transcriptional activation by 
doxycycline stimulation.  Furthermore, separation of Tet-HIV-1 transduction and 
doxycycline addition for nine days did not limit DC or T cell activation (McCauley 
et al., 2017).  This suggests that possible detection or priming mechanisms prior 
to integration and expression are unnecessary for HIV-1 transcription dependent 
innate activation.  In contrast, inhibition of CRM1 HIV-1 RNA export with 
leptomycin or with Rev/RRE mutations completely abrogated innate activation.  
However, rescue of unspliced export using heterologous retroviral CTEs to 
promote canonical NXF1 RNA export failed to promote DC and macrophage 
activation indicating that Rev-CRM1 mediated transport of unspliced RNA is 
indispensable for detection.   
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Both groups support a model where HIV-1 export of intron containing RNA 
through the CRM1 pathway induces innate activation in DCs, macrophages, and 
T cells.  Furthermore, the authors suggest that the type 1 interferon response 
induced upon HIV-1 transcription and RNA export may contribute to long term 
pathogenesis in HIV-1 infection.  Chronic inflammation persists in patients on 
effective antiretroviral therapy (ART) regardless of having clinically undetectable 
viral loads (Brenchley et al., 2006; Deeks et al., 2013; Sinha et al., 2016; Taiwo 
et al., 2013).  It is known that the HIV-1 proviral reservoir in patients on ART is 
composed of only a small percentage of intact, replication competent sequences 
with the majority harboring deactivating mutations and deletions (Barton et al., 
2016; Bruner et al., 2016; Cohn et al., 2018; Huang et al., 2018; Lorenzi et al., 
2016; Pollack et al., 2017).  A priori, any cell harboring a provirus capable of Rev-
CRM1 export, regardless of its ability to continue replication, could initiate 
transcription and induce an antiviral response contributing to systemic 
inflammation (Akiyama et al., 2017; McCauley et al., 2017).   
 
1.7  Perspectives 
DCs are highly refractory to productive HIV-1 infection with blocks to both CD4-
Env mediated viral entry as well as reverse transcription as due to SAMHD1.  
HIV-1 entry into DCs can be promoted experimentally through VSV-G 
pseudotyping allowing for CD4-Env independent fusion (Granelli-Piperno et al., 
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2000).  Furthermore, the addition of the SIV/HIV-2 Vpx protein leads to SAMHD1 
degradation thereby alleviating the block to reverse transcription (Bergamaschi et 
al., 2009; Sharova et al., 2008; Srivastava et al., 2008).  Under these in vitro 
circumstances, DCs can be efficiently and productively infected.  However, these 
are artificial conditions; useful and essential for experimentation, but not 
reflective of the fact that, in vivo, DCs are not efficiently infected with HIV-1.  
Furthermore, they do not appear to detect HIV-1 in a manner leading to innate 
activation (Fonteneau et al., 2004; Manches et al., 2014; Miller and Bhardwaj, 
2013; Smed-Sörensen et al., 2004).  Instead, HIV-1 antigen is processed and 
presented to T cells in a non-activated state, very likely leading to a stunted and 
ineffective antiviral state.   
Understanding how dendritic cells interact with HIV-1 in both normal and 
optimized systems is important in the development of rational and effective anti-
HIV-1 immunotherapies and vaccines.  Studies have shown that advanced DC 
function correlates with better immune function and disease control.  Elite 
controllers, also known as long term non-progressors (LTNP), are individuals 
who have the capacity to resist progression to AIDS without antiretroviral 
treatment.  T cell responses in elite controllers are much more functional and 
effective at controlling viral replication (Betts et al., 2006; Imami et al., 2013; 
Porichis and Kaufmann, 2011).  It is possible that the improvement to the antiviral 
response is due to superior T cell priming by DCs more reactive to the HIV-1 
virus.  Indeed, dendritic cells of elite controllers have improved capacity to sense 
 
 
37 
 
 
HIV-1 and to induce type 1 interferon as a result (Manches et al., 2014; Martin-
Gayo et al., 2015, 2018).  As such, this stands as compelling evidence that 
improving DC responsiveness to HIV-1 may be effective as a functional cure or 
prophylactic vaccine to HIV-1 infection. 
   
 
  
 
 
38 
 
 
CHAPTER II 
Intron-containing RNA from the HIV-1 provirus activates type I interferon 
and inflammatory cytokines 
 
 
 
 
 
 
 
 
Adapted from the publication: 
McCauley, S.M., Kim, K., Nowosielska, A., Dauphin, A., Diehl, W.E., and Luban, 
J. (2017). Intron-containing RNA from the HIV-1 provirus activates type I 
interferon and inflammatory cytokines. bioRxiv  
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2.1  Summary 
HIV-1-infected people who take drugs that suppress viremia to undetectable 
levels are protected from developing AIDS (Günthard et al., 2016).  Nonetheless, 
these individuals have chronic inflammation associated with heightened risk of 
cardiovascular pathology (Brenchley et al., 2006; Freiberg et al., 2013; Sinha et 
al., 2016). HIV-1 establishes proviruses in long-lived CD4+ memory T cells, and 
perhaps other cell types (Jiang et al., 2015; Kandathil et al., 2016; Siliciano et al., 
2003), that preclude elimination of the virus even after years of continuous 
antiviral therapy (Davey et al., 1999). Though the majority of proviruses that 
persist during antiviral therapy are defective for production of infectious virions 
(Bruner et al., 2016), many are expressed (Wiegand et al., 2017), raising the 
possibility that the HIV-1 provirus or its transcripts contribute to ongoing 
inflammation. Here we found that the HIV-1 provirus activated innate immune 
signaling in isolated dendritic cells, macrophages, and CD4+ T cells. Immune 
activation required transcription from the HIV-1 provirus and expression of 
CRM1-dependent, Rev-dependent, RRE-containing, unspliced HIV-1 RNA. If rev 
was provided in trans, all HIV-1 coding sequences were dispensable for 
activation except those cis-acting sequences required for replication or splicing. 
These results indicate that the complex, post-transcriptional regulation intrinsic to 
HIV-1 RNA is detected by the innate immune system as a danger signal, and that 
drugs which disrupt HIV-1 transcription or HIV-1 RNA metabolism would add 
qualitative benefit to current antiviral drug regimens. 
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2.2  HIV-1 transduction matures dendritic cells  
To determine if HIV-1 proviruses activate innate immune signaling, human blood 
cells were transduced with single-cycle vectors, either a full-length, single-cycle 
HIV-1 clone with a frameshift in env and eGFP in place of nef (HIV-1-GFP)  (He 
et al., 1997), or a minimal 3-part lentivector encoding GFP (Fig. 2.1a, Table 2.1) 
(Pertel et al., 2011). Monocyte derived dendritic cells (DCs) were challenged 
initially since HIV-1 transduction of these specialized antigen-presenting cells 
activates innate immune signaling (Berg et al., 2012; Gao et al., 2013; Landau, 
2014; Manel et al., 2010; Rasaiyaah et al., 2013). To increase the efficiency of 
provirus establishment, vectors were pseudotyped with the vesicular stomatitis 
virus glycoprotein (VSV G) and delivered concurrently with virus-like particles 
(VLPs) bearing SIVMAC251 Vpx (Fig. 2.1b) (Goujon et al., 2006; Pertel et al., 
2011). Transduction efficiency, as determined by flow cytometry for GFP-positive 
cells, was 30-60% (Fig. 2.1b), depending on the blood donor. 
DCs matured in response to HIV-1-GFP transduction, as indicated by increased 
mean fluorescence intensity of co-stimulatory or activation molecules, including 
HLA-DR, CD80, CD86, CD40, CD83, CCR7, CD141, ISG15, MX1, and IFIT  
(Sousa, 2006) (Fig. 2.1b, c). Maturation was evident among both GFP positive 
and negative cells (Fig. 2.1b), the latter resulting from activation in trans by type 
1 IFN as several others have shown (Manel et al., 2010; Rasaiyaah et al., 2013). 
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Identical results were obtained with full-length, single-cycle vectors generated 
from primary, transmitted/founder clones that were derived by single genome 
sequencing, HIV-1-AD17 (Parrish et al., 2013), HIV-1-Z331M-TF (Deymier et al., 
2015), and HIV-1-ZM249M (Salazar-Gonzalez et al., 2009), the first virus being 
clade B, the other two clade C (Fig. 2.1d). A single cycle HIV-2 vector induced 
maturation, indicating that this innate response was not unique to HIV-1 (Fig. 
2.1e).  
DCs matured when HIV-1-GFP transduction efficiency was augmented with 
nucleosides (Reinhard et al., 2014), rather than with SIV VLPs, indicating that 
Vpx was not required for maturation (Fig. 2.1f). DCs were then challenged with 
replication-competent HIV-1 bearing CCR5-tropic Env, either T cell-tropic or 
macrophage-tropic (Granelli-Piperno et al., 1998), with or without Vpx-VLPs (Fig. 
2.1g). The percent of cells transduced by vector bearing either Env increased 
with Vpx, though DC maturation was observed under all conditions, even among 
the very few DCs transduced by T cell-tropic env (see inset of Fig. 2.1g). These 
results indicate that neither VSV G, nor Vpx, nor high-titer infection, was required 
for DC maturation. 
In response to transduction with HIV-1-GFP, steady-state CXCL10, IFNB1, and 
IL15 mRNAs reached maximum levels at 48 hrs, increasing 31,000-, 92-, and 
140-fold relative to mock-treated cells, respectively (Fig. 2.1h, i). 
Correspondingly, IFNα2, CCL7, IL-6, CXCL10, and TNFα proteins accumulated 
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in the supernatant (Fig. 2.1j). In contrast to the results with HIV-1-GFP, there 
were no signs of maturation after transduction with the 3-part minimal lentivector 
(Fig. 2.1b, h, j). 
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Figure 2.1 
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Figure 2.1  
(continued) 
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Figure 2.1  
(continued) 
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Figure 2.1  HIV-1 transduction matures DCs. 
a, Schematic of HIV-1-GFP, with frameshift in env (red line) and gfp in place of 
nef (He et al., 1997), and of the minimal lentivector, with self-inactivating ΔU3 
LTR (Zufferey et al., 1998) and gfp driven by the SFFV promoter (Pertel et al., 
2011). Unless indicated otherwise, vectors were pseudotyped with VSV G and 
cells were co-transduced with SIVMAC251 VLPs bearing Vpx. b, Flow cytometry of 
DCs for GFP and CD86, after treatment as indicated. c, Flow cytometry 
histograms for the indicated markers 72 hrs after DC transduction with HIV-1 
(red) or mock (black). d, Flow cytometry of DCs for GFP and CD86 after 
transduction with single-cycle clones, HIV-1-NL4-3, HIV-1-AD17, HIV-1-Z331M-
TF, or HIV-1-ZM249M. e, Transduction of DCs with HIV-2-ROD-GFP, single-
cycle vector. f, DC transduction with HIV-1-GFP in the absence of Vpx and the 
presence of 2 mM nucleosides. g, 12 day spreading infection on DCs, with 
macrophage-tropic or T cell-tropic, replication-competent HIV-1, with or without 
SIV VLPs. h, qRT-PCR quantitation of CXCL10 (black), IFNB1 (gray), or IL15 
(white) mRNAs from DCs transduced with HIV-1-GFP. i, qRT-PCR quantitation 
of CXCL10 mRNA in DCs transduced with either HIV-1-GFP or minimal 
lentivector, assessed at the indicated times post-transduction. j, Cytokines in DC 
supernatant as assessed by luminex, 72 hrs after transduction with HIV-1-GFP 
(black) or minimal lentivector (gray). 
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Shown are blood donor data representative of n=12 (b), n=4 (c, d, e, f, h, i, j), or 
n=8 (g). To determine significance, the MFI of all live cells for each sample was 
calculated as fold-change of variable versus negative control for the indicated 
marker. The exception being (g) where the MFI of only GFP+ cells was 
compared. Combined flow cytometry MFI fold change data for all donor 
replicates is represented by the associated dot plots. Significance was tested in 
all flow cytometry data by one-way ANOVA with Dunnett’s post-test comparing 
test against minimal lentivector negative (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 
0.001, **** = p ≤ 0.0001).  qRT-PCR and Luminex data are displayed as mean 
+/- SD, with significance test against correspondingly-timed negative control by 
two-way ANOVA, Dunnett’s post-test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, 
**** = p ≤ 0.0001).  
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2.3  Maturation requires integration, independent of coding sequence 
To determine if early stages in the HIV-1 replication cycle were necessary for 
maturation, reverse transcription was inhibited by nevirapine (NVP) or the HIV-1 
RT mutant D185K/D186L, and integration was inhibited with Raltegravir (RALT) 
or the HIV-1 IN mutant D116A (Table 2.1, 2.2), as previously described (De Iaco 
and Luban, 2011). Each of these four conditions abrogated maturation, as 
indicated by cell surface CD86 (Fig. 2.2a) and steady-state CXCL10 mRNA (Fig. 
2.2b). When integration was inhibited, CXCL10 mRNA increased in response to 
challenge with HIV-1-GFP, but levels were nearly 1,000 times lower than when 
integration was not blocked (Fig. 2.2b). 
HIV-1 virion RNA and newly synthesized viral cDNA are reported to be detected 
by RIG-I and by cGAS, respectively (Berg et al., 2012; Gao et al., 2013). Signal 
transduction downstream of both sensors requires TBK1 and IRF3. The TBK1 
inhibitor BX795 (Table 2.1) blocked DC maturation in response to cGAMP but 
had no effect on maturation after HIV-1-GFP transduction (Fig. 2.2c). Moreover, 
IRF3 knockdown (Table 2.1) (Pertel et al., 2011) suppressed activation of CD86 
or ISG15 in response to cGAMP, but not in response to HIV-1 transduction (Fig. 
2.2c). Similarly, no effect on HIV-1-induced DC maturation was observed with 
knockdown of IRF1, 5, 7, or 9, or of STAT1 or 2, (Pertel et al., 2011), or of 
pharmacologic inhibition of CypA, PKR, c-Raf, IkBa, NF-kB, MEK1+2, p38, JNK, 
Caspase 1, pan-Caspases, ASK1, eIF2a, TBK1, IKKe, TAK1, or NLRP3. Under 
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the conditions used here, then, DC maturation required reverse transcription and 
integration but was independent of most well characterized innate immune 
signaling pathways. 
Completion of the HIV-1 integration reaction requires cellular DNA repair 
enzymes (Craigie and Bushman, 2012). That DCs did not mature in response to 
transduction with minimal lentivectors (Fig. 2.1b, i, j) indicates that activation of 
the DNA repair process is not sufficient, and that transcription from the HIV-1-
GFP provirus must be necessary for maturation. Indeed, gag expression from an 
integrated vector has been reported to be necessary for DC maturation (Manel et 
al., 2010). To determine if any individual HIV-1 proteins were sufficient to mature 
DCs, a minimal lentivector was used to express codon optimized versions of 
each of the open reading frames possessed by HIV-1-GFP (Fig. 2.2d, Table 2.1). 
Among these vectors was a gag-expression vector that produced as much p24 
protein as did HIV-1-GFP (Fig. 2.2d). None of these vectors matured DCs (Fig. 
2.2d). 
HIV-1-GFP was then mutated to determine if any protein coding sequences were 
necessary for DC maturation. For these and any subsequent experiments in 
which an essential viral component was disrupted within HIV-1-GFP, the factor in 
question was provided in trans, either during assembly in transfected HEK293 
cells, or within transduced DCs, as appropriate (see Methods). Mutations that 
disrupted both gag and pol, either a double frameshift in gag, or a mutant in 
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which the first 14 ATGs in gag were mutated, abolished synthesis of CA (p24) yet 
retained full maturation activity (Fig. 2.2e, Table 2.1). Deletion mutations 
encompassing gag/pol, vif/vpr, vpu/env, or nef/U3-LTR, each designed so as to 
leave cis-acting RNA elements intact, all matured DCs (Fig. 2.2f, Table 2.1). 
These results indicate that these HIV-1-GFP RNA sequences, as well as the 
proteins that they encode, were not required for DC maturation. 
Tat and Rev coding sequences were individually disrupted by combining start 
codon point mutations with nonsense codons that were silent with respect to 
overlapping reading frames (Table 2.1). Neither Δtat nor Δrev matured DCs upon 
transduction (Fig. 2.2g). However, DCs matured upon co-transduction of Δtat and 
Δrev, or when minimal lentivectors expressing codon-optimized Tat and Rev 
were co-transduced in trans (Fig. 2.2g). These results indicate that the 
maturation defect with the individual vectors was due to disruption of Tat and Rev 
function, and not due to a cis-acting defect of the mutant RNA. 
The minimal 3-part lentivector expressed GFP from a heterologous promoter and 
had a deletion mutation encompassing the essential, cis-acting TATA box and 
enhancer elements (Zufferey et al., 1998), as well as in the trans-acting tat and 
rev, that inactivated the promoter in the proviral 5’ LTR (Fig. 2.1a). To test the 
importance of LTR-driven transcription for DC maturation by the HIV-1 provirus, 
the HIV-1 LTR was restored in the minimal vector (Fig. 2.2h, Table 1); in addition, 
GFP was inserted in place of gag as a marker for LTR expression, and the 
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heterologous promoter was used to drive tat, rev, or both genes separated by 
P2A coding sequence (Fig. 2h). None of the LTR-driven, minimal vectors 
matured DCs (Fig. 2.2h). 
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Figure 2.2   
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 Figure 2.2  (continued) 
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Figure 2.2  
(continued)  
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Figure 2.2  HIV-1 RNA regulation is necessary for DC maturation, but LTR-
driven transcription is insufficient and coding sequences are not 
necessary. 
a, Assessment of GFP and CD86 by flow cytometry following transduction with, 
top, HIV-1-GFP in the presence of 5 µM nevirapine (RTi), 10 µM raltegravir (INi), 
or no drug, and, bottom, HIV-1-GFP bearing mutant RT-D185K/D186L (RTmut) 
or mutant IN-D116A (INmut). b, qRT-PCR quantitation of CXCL10 mRNA from 
the same DCs as in (a). c, DCs treated with 1 µM of the TBK1 inhibitor BX795, or 
expressing shRNAs targeting either IRF3 or luciferase control(Pertel et al., 2011), 
were challenged with 25 µg/mL cGAMP or HIV-1-GFP and assayed by flow 
cytometry for CD86 and ISG15. d, Flow cytometry of DCs after transduction with 
minimal lentivectors expressing codon optimized HIV-1 genes; e, HIV-1-GFP in 
which translation was disrupted by two frameshifts in gag or by mutation of the 
first 14 AUGs in gag; f, HIV-1-GFP bearing deletion mutations encompassing 
gag/pol, vif/vpr, vpu/env, or nef/U3-LTR; g, HIV-1-GFP bearing mutations in tat or 
rev, co-transduced with both mutants, or co-transduced with minimal vector 
expressing tat and rev in trans; or h, minimal lentivector with GFP in place of 
gag, SFFV promoter driving expression of tat, rev, or both, and repaired U3 in the 
3’ LTR; the latter restores 5’-LTR-directed transcription to the provirus as a result 
of the reverse transcription strand-transfer reactions. When an essential viral 
component was disrupted within HIV-1-GFP, the factor in question was provided 
in trans, either during assembly in transfected HEK293 cells, or within transduced 
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DCs, as appropriate (see Methods). Shown are blood donor data representative 
of n=6 (a, b, e, f), n=12 (c, g, h), n=8 (d).  
To determine significance, the MFI of individual flow cytometry samples was 
calculated as fold-change of variable versus negative control for the indicated 
marker. Combined flow cytometry MFI fold change data for all donor replicates is 
represented by the associated dot plots. Significance was tested in all flow 
cytometry data by one-way ANOVA with Dunnett’s post-test comparing test 
against minimal lentivector negative (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, 
**** = p ≤ 0.0001).  qRT-PCR data are displayed as mean +/- SD, with 
significance test against correspondingly-timed negative control by two-way 
ANOVA, Dunnett’s post-test (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** = p ≤ 
0.0001).  
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2.4  Maturation requires transcription and Rev-mediated export 
To determine if tat was necessary for DC maturation, tat and TAR were mutated 
in HIV-1-GFP and the LTR promoter was modified to be tetracycline-inducible, as 
previously described (Das and Berkhout, 2016) (Tet-HIV-1 in Fig. 2.3a Table 
2.1). The doxycycline-dependent reverse transactivator (rtTA) was delivered in 
trans by lentivector. In the presence of doxycycline (Table 2.2), Tet-HIV-1 and 
rtTA matured DCs when given in combination, but neither vector matured DCs 
when given in isolation (Fig. 2.3a). Additionally, the magnitude of cell surface 
CD86 was dependent on the doxycycline concentration, indicating that 
maturation was dependent on the level of HIV-1 transcription (Fig. 3b). These 
results demonstrated that tat was not required for maturation, so long as the 
provirus was expressed. 
To ascertain whether rev was necessary for DC maturation, the RTE from a 
murine intracisternal A-particle retroelement (IAP), and the CTE from SRV-1, 
were inserted in place of nef (HIV-RTE/CTE in Fig. 2.3c, Table 2.1) (Smulevitch 
et al., 2006). Each of these elements utilizes the NXF1 nuclear RNA export 
pathway, thereby bypassing the need for CRM1 and rev (Fornerod et al., 1997). 
p24 levels with this construct were similar to those of HIV-1-GFP, indicating that 
unspliced RNA was exported from the nucleus at least as well as with Rev (Fig. 
2.3c). Nonetheless, the HIV-RTE/CTE vector did not mature DCs (Fig. 2.3c), 
indicating that maturation was dependent upon rev and CRM1-mediated RNA 
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export. Consistent with this conclusion, the CRM1 inhibitor leptomycin B (Table 
2.2) abrogated DC maturation by HIV-1-GFP (Fig. 2.3d). In contrast, leptomycin 
B had no effect on DC maturation in response to Sendai virus infection (Fig. 
2.3e). ISG15 was used to monitor maturation in these experiments since, as 
previously reported for DCs, leptomycin B altered background levels of CD86 
(Chemnitz et al., 2010). 
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Figure 2.3 
 
 
60 
 
 
Figure  2.3 
Continued   
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Figure 2.3  Rev-mediated RNA export is necessary for DC maturation but 
Tat is dispensable 
a, 2xTet operator(Das and Berkhout, 2016) was cloned into the 3’LTR of HIV-1-
GFPΔtat to generate Tet-HIV-1; strand-transfer reactions that occur during 
reverse transcription generate a Tet-regulated 5’-LTR in the provirus. DCs 
transduced with Tet-HIV-1, rtTA3, or both, were treated for 3 d with 500 ng/mL 
doxycycline and assayed by flow cytometry for p24, GFP, and CD86. b, DCs co-
transduced with Tet-HIV-1 and rtTA3 were treated with increasing concentrations 
of doxycycline. c, To generate HIV-1-RTE/CTE, the RTEm26CTE element 
(Smulevitch et al., 2006) was cloned in place of nef in HIV-1-GFPΔrev/ΔRRE. 
DCs were transduced with the indicated vectors and assessed for p24 and 
ISG15 by flow cytometry. d, DCs were treated with 25 nM leptomycin B, 
transduced with HIV-1-GFP, and assessed for GFP and ISG15 by flow 
cytometry. e, DCs were treated with 25 nM leptomycin B, transduced with HIV-1-
GFP or infected with Sendai virus (SeV), and assessed for ISG15 by flow 
cytometry. Shown are blood donor data representative of n=10 (a, c), n=4 (b), 
n=6 (d, e).  
To determine significance, the MFI of individual flow cytometry samples was 
calculated as fold-change of variable versus negative control for the indicated 
marker. Combined flow cytometry MFI fold change data for all donor replicates is 
represented by the associated dot plots. Significance was tested in all flow 
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cytometry data by one-way ANOVA with Dunnett’s post-test comparing test 
against minimal lentivector negative (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, 
**** = p ≤ 0.0001).  
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2.5  HIV-1 transcription activates macrophages and CD4+ T cells 
To determine if innate immune detection of HIV-1 was unique to DCs, monocyte-
derived macrophages and CD4+ T cells were examined. In response to 
transduction with HIV-1-GFP, macrophages upregulated CD86, ISG15, and HLA-
DR, and CD4+ T cells upregulated MX1, IFIT1, and HLA-DR (Fig. 2.4a). DCs, 
macrophages, and CD4+ T cells were then transduced side-by-side with mutant 
constructs to determine if the mechanism of innate immune activation was similar 
to that in DCs. As with DCs, HIV-1-GFP bearing the Δgag/pol deletion activated 
macrophages and CD4+ T cells (Fig. 2.4b). Also in agreement with the DC 
results, neither the minimal lentivector, nor HIV-1-GFP bearing mutations in 
integrase, tat, or rev, matured any of the three cell types (Fig. 2.4b). 
CD4+ T cells were infected with either macrophage-tropic or T cell-tropic HIV-1 to 
determine whether replication-competent HIV-1 was similarly capable of innate 
immune activation in these cells, in the absence of VSV G. As with DCs, innate 
immune activation, as detected by MX1 and ISG15 upregulation, was observed 
in cells productively infected with HIV-1, but not with minimal lentivector (Fig. 
2.4c). Finally, to test the effect of HIV-1 proviral RNA on non-activated T cells, 
CD4+ T cells were co-transduced with Tet-HIV-1 and the rtTA3 vector, and 
cultured for 9 days in the absence of stimulation. Upon doxycycline treatment, T 
cells expressed GFP and MX1 (Fig. 2.4d). As in DCs, dose-dependent activation 
was observed with doxycycline (Fig. 2.4d). These data indicate that innate 
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immune activation by HIV-1, in all three cell types, requires integration, 
transcription, and Rev-dependent, HIV-1 intron-containing RNA. 
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Figure 2.4 
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Figure 2.4 
Continued 
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Figure 2.4  Innate immune activation in macrophages and CD4+ T cells by 
HIV-1 proviral transcription 
a, Macrophages and CD4+ T cells were transduced with HIV-1-GFP and assayed 
3 days later for the indicated activation markers. b, DCs, macrophages, and 
CD4+ T cells were challenged with HIV-1-GFP or the indicated mutants. When an 
essential viral component was disrupted within HIV-1-GFP, the factor in question 
was provided in trans during assembly in transfected HEK293 cells, as 
appropriate (see Methods). The upper panel shows flow cytometry of the DCs for 
GFP and CD86. The histograms show CD86 for DCs and macrophages or MX1 
for CD4+ T cells. c, 12 day spreading infections on CD4+ T cells with either 
macrophage-tropic or T cell-tropic, replication-competent HIV-1. d, CD4+ T cells 
were stimulated for 3 days with PHA and IL2, and transduced with Tet-HIV-1 and 
rtTA3. Cells were then cultured without stimulation for 9 days. Doxycycline was 
then added at the indicated concentrations. Cells were assayed for GFP and 
MX1 3 days later. Shown are blood donor data representative of n=6 (a), n=4 (b, 
c, d).  
To determine significance, the MFI of individual flow cytometry samples was 
calculated as fold-change of variable versus negative control for the indicated 
marker. Combined flow cytometry MFI fold change data for all donor replicates is 
represented by the associated dot plots. Significance was tested in all flow 
cytometry data by one-way ANOVA with Dunnett’s post-test comparing test 
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against minimal lentivector negative (* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, 
**** = p ≤ 0.0001).  
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2.6  Implications for research and antiviral therapy 
The HIV-1 LTR generates a single primary transcript that gives rise to over 100 
alternatively spliced RNAs (Ocwieja et al., 2012). The full-length, unspliced, 
intron-bearing transcript acts as viral genomic RNA in the virion and as mRNA for 
essential gag- and pol-encoded proteins. Expression of the unspliced transcript 
requires specialized viral and cellular machinery, HIV-1 Rev and CRM1(Fornerod 
et al., 1997), in order to escape from the spliceosome. Results here indicate that 
unspliced or partially spliced HIV-1 RNA is detected by human cells as a danger 
signal, as has been reported for inefficiently spliced mRNAs from transposable 
elements in distantly related eukaryotes (Dumesic et al., 2013). Transposable 
elements are mutagenic to the host genome and it stands to reason that 
molecular features such as transcripts bearing multiple, inefficient splice signals 
characteristic of retrotransposons, would activate innate immune signaling 
pathways. 
HIV-1 genomic RNA contains extensive secondary and higher order structures 
that could be detected by innate immune sensors. Our knockdown of IRF3 and 
inhibition of TBK1, both required for signal transduction of the RNA sensors RIG-
I, MDA5, and TLR3, did not impede HIV-1 maturation of DCs (Figure 2.2c). 
Furthermore, we suppressed an extensive list of innate signaling pathways and 
sensors including knockdowns of IRF’s 1, 5, 7, and 9, STAT’s 1 and 2, as well as 
pharmacologic inhibition of CypA, PKR, c-Raf, IkBa, NF-kB, MEK1+2, p38, JNK, 
 
 
70 
 
 
Caspase 1, pan-Caspases, ASK1, eIF2a, IKKe, TAK1, or NLRP3 (Table 2.2). 
None of these perturbations had any effect on limiting innate immune activation 
by HIV-1, suggesting requirement for an alternative detection mechanism. Such 
mechanisms might include uncharacterized RNA sensors, direct detection of 
stalled splicing machinery, or overload of the CRM1 nuclear export pathway 
itself. 
The replication competent HIV-1 reservoir in memory CD4+ T cells has a 44 wk 
half-life and thus patients must take antiviral medication for life (Crooks et al., 
2015). Long-lived, replication competent HIV-1 reservoirs in other cell types have 
not been clearly demonstrated, but these may also contribute to the HIV-1 
reservoir (Kandathil et al., 2016). The common genetic determinants in HIV-1 for 
maturation of CD4+ T cells, macrophages, and DCs suggests that HIV-1 is 
detected by a mechanism that is conserved across cell types, and that this 
mechanism would be active in any cell type that possesses a transcriptionally 
active provirus. Data here show that proviruses need not be replication 
competent to contribute to inflammation. Rather, HIV-1 transcription and export 
of unspliced RNA, regardless of replication competence, is sufficient to induce 
immune activation. Consistent with our findings, T cell activation correlates 
directly with the level of cell-associated HIV-1 RNA in patients receiving 
antiretroviral therapy (El-Diwany et al., 2017). Furthermore, our data suggests 
that new drugs that block HIV-1 transcription, Tat-mediated transcriptional 
elongation, or Rev-mediated preservation of unspliced transcripts(Mousseau et 
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al., 2015), would limit inflammation, and offer an important addition to the current 
anti-HIV-1 drug armamentarium. 
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Table 1  Plasmids used in this study 
Plasmid Name Purpose Notes 
pBS NL4-3 envFS 
eGFP 
Single-cycle, full-
length HIV-1 
“HIV-1-GFP” in the manuscript. HIV-1 NL4-3 
in pBluescript, flanking host sequences 
deleted, frameshift in env, eGFP in place of 
nef(He et al., 1997) 
pUC57mini NL4-3 
Δenv eGFP 
HIV-1 clade B 
molecular clone 
Molecular clone of NL4-3 with deletion of 79 
nucleotides following the Env signal peptide 
and eGFP in place of nef 
pUC57mini AD17 
Δenv eGFP 
HIV-1 clade B 
molecular clone 
Molecular clone of transmitted/founder virus 
HIV-1-AD17(Parrish et al., 2013) with deletion 
of 79 nucleotides following the Env signal 
peptide and eGFP in place of nef 
pUC57mini Z331M-
TF Δenv eGFP 
HIV-1 clade C 
molecular clone 
Molecular clone of transmitted/founder virus 
HIV-1-Z331M-TF(Deymier et al., 2015) with 
deletion of 79 nucleotides following the Env 
signal peptide and eGFP in place of nef 
pUC57mini 
ZM249M Δenv 
eGFP 
HIV-1 clade C 
molecular clone 
Molecular clone of transmitted/founder virus 
HIV-1-ZM249M(Salazar-Gonzalez et al., 
2009) with deletion of 79 nucleotides following 
the Env signal peptide and eGFP in place of 
nef 
 pROD9 ∆env 
eGFP 
HIV-2 ROD 
molecular clone 
Molecular clone of HIV-2-ROD. Contains 
frameshift in env and eGFP in place of Nef 
pMD2.G VSV G Pseudotype HIV-1 vectors with VSV G 
psPAX2 HIV-1 gag-pol 
"3-part" lentivector or for complementation of 
assembly-incompetent HIV-1 vectors 
SIV3+ 
SIVMAC251 gag-
pol/vpx 
Production of SIV VLPs containing Vpx protein 
pALPS(Pertel et 
al., 2011) 
Minimal 
lentivector 
Includes cis-acting elements required for 
reverse transcription and integration, psi RNA 
packaging element, RRE, cPPT, PPT, 
mutation in the 3’LTR U3 that eliminates LTR-
based transcription, and SFFV promoter to 
express genes of interest. 
pALPS eGFP eGFP lentivector Encodes eGFP 
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pALPS gag gag lentivector Encodes codon optimized NL4-3 gag 
pALPS env env lentivector Encodes codon optimized JR-CSF env 
pALPS tat tat lentivector Encodes codon optimized NL4-3 tat 
pALPS rev rev lentivector Encodes codon optimized NL4-3 rev 
pALPS vif vif lentivector Encodes codon optimized NL4-3 vif 
pALPS vpr vpr lentivector Encodes codon optimized NL4-3 vpr 
pALPS vpu vpu lentivector Encodes codon optimized NL4-3 vpu 
pALPS tat-P2A-rev 
tat and rev 
lentivector 
Lentivector expressing codon optimized NL4-3 
tat and rev linked by P2A peptide coding 
sequence (GSGATNFSLLKQAGDVEENPGP) 
pBS NL4-3 envFS 
eGFP RT-
D185K/D186L(De 
Iaco and Luban, 
2011) 
RT mutant 
pBS NL4-3 envFS eGFP with mutation that 
disrupts RT catalytic activity   
pBS NL4-3 envFS 
eGFP IN-
D116A(De Iaco 
and Luban, 2011) 
IN mutant 
pBS NL4-3 envFS eGFP with mutation that 
disrupts IN catalytic activity  
pBS NL4-3 envFS 
eGFP PR-D25A(De 
Iaco and Luban, 
2011) 
PR mutant 
pBS NL4-3 envFS eGFP with mutation that 
disrupts Protease catalytic activity 
pALPS puro 
miR30-
L1221(Pertel et al., 
2011) 
Luciferase 
knockdown 
negative control for knockdowns 
target site: CTTGTCGATGAGAGCGTTTGT 
pALPS puro 
miR30-IRF1(Pertel 
et al., 2011) 
IRF1 knockdown Target site TTGCTCTTAGCATCTCGGCTG 
pALPS puro 
miR30-IRF3(Pertel 
et al., 2011) 
IRF3 knockdown Target site ATCAGATCTACAATGAAGGGC 
pALPS puro 
miR30-IRF5(Pertel 
et al., 2011) 
IRF5 knockdown Target site TATTTCCCTGTCTCCTTGGCC 
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pALPS puro 
miR30-IRF7(Pertel 
et al., 2011) 
IRF7 knockdown Target site ATAAGGAAGCACTCGATGTCG 
pALPS puro 
miR30-IRF9(Pertel 
et al., 2011) 
IRF9 knockdown Target site AATTATCACAAAGAGGACAGG 
pALPS puro 
miR30-
STAT1(Pertel et 
al., 2011) 
STAT1 
knockdown 
Target site ATATCCAGTTCCTTTAGGGCC 
pALPS puro 
miR30-
STAT2(Pertel et 
al., 2011) 
STAT2 
knockdown 
Target site TTTAAGTTCCACAGACTTGGA 
pALPS puro 
miR30-TAK1(Pertel 
et al., 2011) 
TAK1 knockdown Target site AGCGCCCTTCAATGGAGGAAAT 
pALPS_3’LTR 
GFP@gag start 
SFFV- 
U3+ lentivector 
GFP at gag start 
SFFV promoter 
Repaired U3 allows LTR-based transcription 
by the provirus with GFP as a marker for 
expression. WPRE was deleted. 
pALPS_3’LTR 
GFP@gag start 
SFFV tat 
U3+ lentivector  
GFP at gag start 
SFFV-tat 
LTR drives GFP and internal SFFV promoter 
drives codon optimized tat 
pALPS_3’LTR 
GFP@gag start 
SFFV rev 
U3+ lentivector 
GFP at gag start 
SFFV-rev 
LTR drives GFP and internal SFFV promoter 
drives codon optimized rev 
pALPS_3’LTR 
GFP@gag start 
SFFV tat-P2A-rev 
U3+ lentivector 
with SFFV-
tatP2Arev 
LTR drives GFP and internal SFFV promoter 
drives codon optimized tat and rev. 
pNL4-3 envFS 
eGFP gag2xFS 
No Gag 
synthesis 
1st frameshift is CG nucleotide insertion in MA 
at nt 832.  2nd is a CTAG addition in CA at nt 
1508. 
pNL4-3 envFS 
eGFP NoStarts 
No Gag 
synthesis 
All ATGs from the start of gag to NC mutated 
to ATC except the first which was mutated to 
ACG 
pBS NL4-3 envFS 
eGFP Δgag/pol 
gag-pol deletion 
Deletion from the start of gag until 229 bases 
before the cPPT 
pNL4-3 envFS 
vif/vpr deletion 
Deletion from NL4-3 nt 5582-6199 
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eGFP Δvif/vpr encompassing Vif and Vpr coding sequence 
pNL4-3 envFS 
eGFP Δvpu/env 
vpu/env deletion 
Deletion from NL4-3 nt 6054-7489 
encompassing all of vpu and env until before 
the RRE 
pBS NL4-3 envFS 
eGFP Δnef/U3 
nef/U3 deletion 
Deletion from NL4-3 nt 8911-9022 and 9088-
9377.  This deletes nef and U3 LTR 
sequences 
pBS NL4-3 envFS 
eGFP 5'CMV Δtat 
HIV-1 with 
inactivating 
mutations in tat 
tat ATG->ACG (silent in vpr reading frame), nt 
78 mutated T->G to change Tyr to stop codon, 
nt 116 mutated T->C to disrupt Met, 5'LTR 
replaced with CMV-R-U5 from pALPS for tat-
independent transcription in HEK293E cells. 
pBS NL4-3 envFS 
eGFP Δrev 
HIV-1 with 
inactivating 
mutations in rev 
All mutations in rev are silent with respect to 
the tat reading frame. Start ATG->ACG and 
nts 68-71 were mutated AGC->TCA to change 
tyrosine to a stop. 
pBS NL4-3 envFS 
eGFP 5'CMV Δtat 
ΔTARx2_d2TetOp(
Das and Berkhout, 
2016) 
Tet-inducible, tat-
independent HIV-
1 
2xTet Operator inserted between NFkB and 
Sp1 sites in U3 of HIV-1 Δtat with 5' CMV-R-
U5.  5’ and 3’ TAR elements were mutated to: 
5’-
GGTCTCTCTGGTTAGACCAGAAAGGAGCA
TTGGAGCTCTCTGGCTAACTAGGGAACCC-
3’ 
pALPS 
rtTA3_V14(Das 
and Berkhout, 
2016) 
rtTA3 lentivector  
Codon optimized rtTA3 used in trans with Tet 
inducible HIV-1 
pSC101 NL4-3 
envFS Δrev ΔRRE 
RTEm26CTE(Smul
evitch et al., 2006) 
Rev (CRM1) 
independent HIV-
1 
HIV-1 ΔRev was cloned into pSC101 and 
modified to include an RTEm26CTE element 
in order to utilize the NXF1 RNA export 
pathway.  The RRE was also mutated. 
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Table 2  Drugs and maturation effects  
Drug Action Source 
Working 
concentration 
HIV-1 DC 
maturation 
Doxycycline rtTA3 activator Sigma (D9891) 10-1000 ng/mL - 
cGAMP STING activator 
Invivogen (tlrl-
nacga23) 
25 µg/mL - 
PHA-P T cell mitogen Sigma (L1668) 5 μg/mL - 
2′deoxyguanosine 
monohydrate 
For nucleoside assisted 
transductions 
Sigma (D0901) 2 mM - 
2’ deoxythymidine 
For nucleoside assisted 
transductions 
Sigma (T1895) 2 mM - 
2′deoxyadenosine 
monohydrate 
For nucleoside assisted 
transductions 
Sigma (D8668) 2 mM - 
2′deoxycytidine 
hydrochloride 
For nucleoside assisted 
transductions 
Sigma (D0776) 2 mM - 
Sendai Virus (SeV) 
Cantell strain 
Challenge virus 
Charles River Labs 
(VR-907) 
200 HA units/mL - 
Nevirapine 
Reverse transcriptase 
inhibitor 
NIH AIDS reagent 
program (4666) 
5 µM Inhibits 
Raltegravir Integrase inhibitor 
NIH AIDS reagent 
program (11680) 
10 µM Inhibits 
Leptomycin CRM1 inhibitor 
Invivogen 
 (tlrl-lep) 
25 nM Inhibits 
Cyclosporin A Cyclophilin A inhibitor Sigma (30024) 5 µM No effect 
GW-5075 c-Raf Sigma (G6416) 1, 5, 25 µM No effect 
BAY11-7082 IkB-a Inhibitor 
Invivogen 
 (tlrl-b82) 
1, 2.5, 10 µM No effect 
U0126 
MEK1 and MEK2 
Inhibitor 
Invivogen (tlrl-
u0126) 
10, 25, 50 µM No effect 
SB203580 
p38 MAP Kinase 
Inhibitor 
Invivogen (tlrl-
sb20) 
1, 2.5, 10 µM No effect 
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MCC950 
NLRP3-inflammasome 
inhibitor 
Invivogen (inh-
mcc) 
1, 2.5, 10 µM No effect 
SP600125 JNK Inhibitor 
Invivogen (tlrl-
sp60) 
10, 25, 100 µM No effect 
Z-VAD-FMK Pan-Caspase Inhibitor 
Invivogen 
 (tlrl-vad) 
1, 5, 20 µM No effect 
NQDI-1 ASK1 inhibitor Sigma (SML0185) 1, 10, 100 µM No effect 
ISRIB 
eIF2a phosphorylation 
inhibitor 
Sigma (SML0843) 1, 10, 100 µM No effect 
VX-765 Caspase 1 inhibitor 
Invivogen (inh-
vx765i) 
1, 10, 100 µM No effect 
Dexamethasone 
NF-kB and MAPK 
inhibitor 
Invivogen 
 (tlrl-dex) 
10, 100, 1000 nM No effect 
Chloroquine 
inhibitor of endosomal 
acidification 
Invivogen 
 (tlrl-chq) 
1, 10, 100 µM No effect 
Amlexanox TBK1/IKKε inhibitor 
Invivogen (inh-
amx) 
1, 10, 100 ug/mL No effect 
BX795 TBK1/IKKε inhibitor 
Invivogen 
 (tlrl-bx7) 
0.5, 1, 2 µM No effect 
NG25 trihydrochloride 
TAK1 & LYN, MAP4K2 
and Abl inhibitor 
Sigma (SML1332) 
50, 100, 500, 
1000 nM 
No effect 
5Z-7-Oxozeaenol 
TAK1 & MAP4K2 
inhibitor 
Sigma (O9890) 
50, 100, 500, 
1000 nM 
No effect 
C16 PKR inhibitor Sigma (I9785) 1 µM No effect 
2AP PKR inhibitor 
Invivogen  
(tlrl-apr) 
5 µM No effect 
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2.7  Materials and Methods 
 
Data reporting. No statistical methods were used to predetermine sample size. 
The experiments were not randomized. The investigators were not blinded to 
allocation during experiments and outcome assessment. 
 
Plasmids. The plasmids used here were either previously described or 
generated using standard cloning methods(Pertel et al., 2011). The full list of 
plasmids used here, along with their purpose and characteristics, is provided in 
Supplementary Table 1. All plasmid DNAs with complete nucleotide sequence 
files are available at www.addgene.com. 
 
Cell culture. Cells were cultured at 37°C in 5% CO2 humidified incubators and 
monitored for mycoplasma contamination using the Lonza Mycoplasma 
Detection kit by Lonza (LT07-318). HEK293 cells (ATCC) were used for viral 
production and were maintained in DMEM supplemented with 10% FBS, 20 mM 
L-glutamine (ThermoFisher), 25 mM HEPES pH 7.2 (SigmaAldrich), 1 mM 
sodium pyruvate (ThermoFisher), and 1x MEM non-essential amino acids 
(ThermoFisher). Cytokine conditioned media was produced from HEK293 cells 
stably transduced with pAIP-hGMCSF-co (Addgene #74168), pAIP-hIL4-co 
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(Addgene #74169), or pAIP-hIL2 (Addgene #90513), as previously 
described(Pertel et al., 2011). 
 
Leukopaks were obtained from anonymous, healthy, blood bank donors (New 
York Biologics). As per NIH guidelines 
(http://grants.nih.gov/grants/policy/hs/faqs_aps_definitions.htm), experiments 
with these cells were declared non-human subjects research by the UMMS IRB. 
PBMCs were isolated from leukopaks by gradient centrifugation on Histopaque-
1077 (Sigma-Aldrich). CD14+ mononuclear cells were isolated via positive 
selection using anti-CD14 antibody microbeads (Miltenyi). Enrichment for CD14+ 
cells was routinely >98%.  
 
To generate DCs or macrophages, CD14+ cells were plated at a density of 1 to 2 
x 106 cells/ml in RPMI-1640 supplemented with 5% heat inactivated human AB+ 
serum (Omega Scientific, Tarzana, CA), 20 mM L-glutamine, 25 mM HEPES pH 
7.2, 1 mM sodium pyruvate, and 1x MEM non-essential amino acids (RPMI-HS 
complete) in the presence of cytokines that promote differentiation. DCs were 
generated by culturing monocytes for 6 days in the presence of 1:100 cytokine-
conditioned media containing human GM-CSF and human IL-4. DC preparations 
were consistently >99% DC-SIGNhigh, CD11chigh, and CD14low by flow cytometry.  
Macrophages were generated by culturing for 7 days with GM-CSF conditioned 
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media in the absence of IL-4, and were routinely >99% CD11b.  CD4+ T cells 
were isolated from PBMCs that had been depleted of CD14+ cells, as above, 
using anti-CD4 microbeads (Miltenyi), and were >99% CD4+. CD4+ T cells were 
then cultured in RPMI-1640 supplemented with 10% heat inactivated FBS, 20 
mM L-glutamine, 25 mM HEPES pH 7.2, 1 mM sodium pyruvate, 1x MEM non-
essential amino acids (RPMI-FBS complete), and 1:2000 IL-2 conditioned media. 
Cells from particular donors were excluded from experiments if percent 
enrichment deviated more than 5% from the numbers mentioned above, or if 
there was no increase in activation markers in response to control stimuli (LPS, 
Sendai virus, and wild-type HIV-1-GFP). 
  
HIV-1 vector production. HEK293E cells were seeded at 75% confluency in 6-
well plates and transfected with 6.25 uL Transit LT1 lipid reagent (Mirus) in 250 
μL Opti-MEM (Gibco) with 2.25 µg total plasmid DNA. 2-part HIV-1 vectors based 
on HIV-1-GFP (He et al., 1997) and described in detail in Supplementary Table 1 
were transfected at a 7:1 ratio in terms of µgs of HIV-1 plasmid DNA to pMD2.G 
VSV G expression plasmid DNA(Pertel et al., 2011). 3-part lentivectors were 
produced by transfection of the lentivector genome, psPAX2 GagPol vector, and 
pMD2.G, at a DNA ratio of 4:3:1. These also include 2- part HIV-1-GFP 
constructs that are mutated in such a way as to prevent GagPol, Tat, or Rev 
production. As these would be defective for viral production, psPAX2 was 
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included in the transfections at the same 4:3:1 ratio. VPX-bearing SIV-VLPs were 
produced by transfection at a 7:1 plasmid ratio of SIV3+ to pMD2.G(Pertel et al., 
2011). 12 hrs after transfection, media was changed to the specific media for the 
cells that were to be transduced. Viral supernatant was harvested 2 days later, 
filtered through a 0.45 µm filter, and stored at 4oC. 
 
Virions in the transfection supernatant were quantified by a PCR-based assay for 
reverse transcriptase activity(Pertel et al., 2011). 5 μl transfection supernatant 
were lysed in 5 μL 0.25% Triton X-100, 50 mM KCl, 100 mM Tris-HCl pH 7.4, 
and 0.4 U/μl RNase inhibitor (RiboLock, ThermoFisher). Viral lysate was then 
diluted 1:100 in a buffer of 5 mM (NH4)2SO4, 20 mM KCl, and 20 mM Tris–HCl 
pH 8.3. 10 μL was then added to a single-step, RT PCR assay with 35 nM MS2 
RNA (IDT) as template, 500 nM of each primer (5’-
TCCTGCTCAACTTCCTGTCGAG-3’ and 5’-
CACAGGTCAAACCTCCTAGGAATG-3’), and hot-start Taq (Promega) in a 
buffer of 20 mM Tris-Cl pH 8.3, 5 mM (NH4)2SO4, 20 mM KCl, 5 mM MgCl2, 0.1 
mg/ml BSA, 1/20,000 SYBR Green I (Invitrogen), and 200 μM dNTPs. The RT-
PCR reaction was carried out in a Biorad CFX96 cycler with the following 
parameters: 42°C 20 min, 95°C 2 min, and 40 cycles [95°C for 5 s, 60°C 5 s, 
72°C for 15 s and acquisition at 80°C for 5 s]. 2 part vectors typically yielded 107 
RT units/µL, and 3 part vector transfections yielded 106 RT units/µL. 
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Transductions. 106 DCs/mL, or 5 x 105 macrophages/ml, were plated into 
RPMI-HS complete with Vpx+ SIV-VLP transfection supernatant added at a 
dilution of 1:6. After 2 hrs, 108 RT units of viral vector was added. In some cases, 
drugs were added to the culture media as specified in Supplementary Table 2. In 
most cases, transduced DC were harvested for analysis 3 days following 
challenge. For gene knockdown or for expression of factors in trans, 2 x 106 
CD14+ monocytes/mL were transduced directly following magnetic bead isolation 
with 1:6 volume of SIV-VLPs and 1:6 volume of vector. When drug selection was 
required, 4 µg/mL puromycin was added 3 days after monocyte transduction and 
cells were selected for 3 days.  SIV-VLPs were re-administered in all cases with 
HIV-1 or lentivector challenge. For DCs in Tet-HIV-1 experiments, fresh 
monocytes were SIV-VLP treated and co-transduced with rtTA3 and Tet-HIV-1. 
DCs were harvested 6 days later and treated with indicated doxycycline 
concentrations. 
 
For deoxynucleoside-assisted transductions, DCs were plated at 106 DCs/mL 
and treated with 2mM of combined deoxynucleosides for 2 hrs before 
transduction with HIV-1. Deoxynucleosides were purchased from Sigma-Aldrich 
(2′deoxyguanosine monohydrate, cat# D0901; thymidine, cat# T1895; 
2′deoxyadenosine monohydrate, cat# D8668; 2′deoxycytidine hydrochloride, cat# 
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D0776). A 100 mM stock solution was prepared by dissolving each of the four 
nucleotides at 100 mM in RPMI 1640 by heating the medium at 80°C for 15 min.  
 
CD4+ T cells were stimulated in RPMI-FBS complete with 1:2000 hIL-2 
conditioned media and 5 μg/mL PHA-P. After 3 days, T cells were replated at 106 
cells/mL in RPMI-FBS complete with hIL-2. Cells were transduced with 108 RT 
units of viral vector per 106 cells and assayed 3 days later. T cells were co-
transduced with rtTA3 and Tet-HIV-1 every day for 3 days after PHA stimulation. 
Cells were then replated in RPMI-FBS complete with hIL-2. Transduced T cells 
were cultured for 9 days with fresh media added at day 5. After 9 days, 
doxycycline was added at the indicated concentrations and assayed 3 days later. 
 
Non-HIV-1 Challenge Viruses. Sendai Virus Cantell Strain was purchased from 
Charles River Laboratories. Infections were performed with 200 HA units/ml on 
DCs for 3 days before assay by flow cytometry.   
 
Spreading Infections.  DCs were plated at 106 DCs/mL, in RPMI-HS complete 
media, with or without Vpx+ SIV-VLP transfection supernatant added at a dilution 
of 1:6. After 2 hrs, 108 RT units of HEK-293 transfection supernatant of either 
NL4-3-GFP-JRFL or NL4-3-GFP-JRCSF was added. Each is a construct of 
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pNL4-3 in which env was replaced from the end of the signal peptide (therefore 
retaining the NL4-3 signal peptide and Vpu sequence) to the stop codon with 
either macrophage-tropic JR-FL env (GenBank: U63632.1) or T cell-tropic JR-
CSF env (GenBank: M38429.1). Every 3 days (for a total of 12 days) samples 
were harvested for detection of viral RT activity in supernatant and flow 
cytometry assessment.    
 
CD4+ T cells were stimulated in RPMI-FBS complete with 1:2000 hIL-2 
conditioned media and 5 μg/mL PHA-P. After 3 days, T cells were replated at 106 
cells/mL in RPMI-FBS complete with hIL-2 and transduced with 107 RT units of 
NL4-3-GFP with JRFL (mac tropic) or JRCSF (T tropic) env. Cells were 
harvested every 3 days (for a total of 12 days) and assayed for infectivity and 
activation via flow cytometry. 
 
Cytokine analysis. Supernatants from DCs were collected 3 days following 
transduction with HIV-1-GFP or minimal lentivector. Supernatant was spun at 
500 x g for 5 mins and filtered through a 0.45 μm filter. Multiplex soluble protein 
analysis was carried out by Eve Technologies (Calgary, AB, Canada). 
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qRT-PCR. Total RNA was isolated from 5 x 105 DCs using RNeasy Plus Mini 
(Qiagen) with Turbo DNase (ThermoFisher) treatment between washes. First-
strand synthesis used Superscript III Vilo Master mix (Invitrogen) with random 
hexamers. qPCR was performed in 20 μL using 1× TaqMan Gene Expression 
Master Mix (Applied Biosystems), 1 μL cDNA, and 1 μL TaqMan Gene 
Expression Assays (ThermoFisher) specified in Supplementary Table 3. 
Amplification was on a CFX96 Real Time Thermal Cycler (Bio-Rad) using the 
following program: 95°C for 10 min [45 cycles of 95°C for 15 s and 60°C for 60 s]. 
Housekeeping gene OAZ1 was used as control (Pertel et al., 2011). 
  
Flow cytometry. 105 cells were surface stained in FACS buffer (PBS, 2% FBS, 
0.1% Sodium Azide), using the antibodies in Supplementary Table 4.  Cells were 
then fixed in a 1:4 dilution of BD Fixation Buffer and assayed on a BD C6 Accuri. 
BD Biosciences Fixation and Permeabilization buffers were utilized for 
intracellular staining. Data was analyzed in FlowJo. 
 
Sampling.  All individual experiments were performed with biological duplicates, 
using cells isolated from two different blood donors. Flow cytometry plots in the 
figures show representative data taken from experiments performed with cells 
from the number of donors indicated in the figure legends.   
 
 
86 
 
 
 
Statistical Analysis.  Experimental n values and information regarding specific 
statistical tests can be found in the figure legends. The mean fluorescence 
intensity for all live cells analyzed under a given condition was calculated as fold-
change to negative control/mock. The exception to this methodology was in 
Figures 1g and 4c where the percent infected cells was too low to use MFI for the 
bulk population; in these cases MFI was determined for the subset of cells within 
the GFP+ gate. Significance of flow cytometry data was determined via one-way 
ANOVA. A Dunnett’s post-test for multiple comparisons was applied, where MFI 
fold change was compared to either mock treatment or positive treatment 
depending on the experimental question. qRT-PCR and luminex data was 
analyzed via two-way Anova, with Dunnett’s post-test comparing all samples to 
mock. All ANOVAs were performed using PRISM 7.02 software (GraphPad 
Software, La Jolla, CA).  
 
Data availability. The plasmids described in Supplementary Table 1, along with 
their complete nucleotide sequences, are available at www.addgene.com.  
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CHAPTER III 
Conclusion  
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3.1  Overview and concepts 
The effect of HIV-1 infection on different cell types, especially antigen presenting 
cells such as dendritic cells and macrophages, has been a matter of significant 
research and debate.  DCs are tasked with maintenance of self-tolerance and the 
surveillance of pathogenic attack.  Upon pathogen detection, DCs undergo 
maturation and present cognate peptides to antigen specific T cells.  Competent 
antiviral responses require that the antigen presenting cells communicate the 
nature of the threat with specific coreceptor and cytokine signals.  In contrast, 
even when viral replication is well controlled under antiretroviral treatment, T cell 
responses to HIV-1 infection are well characterized by decreased effector and 
cytotoxic activity.  (Boasso and Shearer, 2008; Day et al., 2006; Khaitan and 
Unutmaz, 2011; Trautmann et al., 2006).  Although chronic systemic 
inflammation has been suggested to contribute to immune exhaustion, the cause 
of T cell dysfunction in HIV-1 infection is largely unknown.  One hypothesis 
proposes that the deficient immune response observed in HIV-1 infection is due, 
at least in part, to the deficient stimulation of HIV-1 specific T cells by DCs that 
do not communicate an antiviral response.   
DCs have been have been shown to resist innate activation following challenge 
with HIV-1 mainly due to their resistance to infection.  Limited CD4 expression 
inhibits Env mediated viral entry (Chauveau et al., 2017; Granelli-Piperno et al., 
2004, 2006; Piguet and Steinman, 2007).  Instead, interactions with c-type lectins 
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like DC-SIGN direct entry into endosomal compartments that drive processing 
and presentation of antigen in the absence of innate stimulation and DC 
maturation.  Notwithstanding the limits to viral entry, the host cytoplasmic 
nuclease SAMHD1 provides a block to reverse transcription that further prohibits 
productive infection of DCs and other non-dividing cells (Bloch et al., 2014; 
Lahouassa et al., 2012; White et al., 2013).  Without recognition of the virus, DCs 
may communicate a tolerogenic response in HIV-1 antigen specific T cells with 
limited antiviral activity (Ahmed et al., 2015; Brown et al., 2010; Day et al., 2006; 
Khaitan and Unutmaz, 2011; Moris et al., 2006; Smed-Sörensen and Loré, 2011; 
Smed-Sörensen et al., 2004).   
   
3.2  Competing mechanisms 
The disagreement and multitude of competing observations and mechanisms 
over how antigen presenting cells and T cells can react to HIV-1 infection is both 
intriguing and discouraging.  Dendritic cells are essential to initiate a potent and 
effective antiviral immune response.  An understanding of whether and how DCs 
detect and communicate HIV-1 infection is crucial to the goal of developing a 
protective, prophylactic vaccine.  Which makes the lack of consensus all the 
more thwarting.  Early studies did not report innate detection of HIV-1 infection in 
DCs regardless of experimental facilitation via VSV-G pseudotyping or Vpx 
addition (Beignon et al., 2005; Fonteneau et al., 2004; Granelli-Piperno et al., 
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2004; Smed-Sörensen et al., 2005).  However, more recent studies have shown 
strong evidence of sensing of HIV-1 infection both with and without artificial 
assistance.  However, while many conflicting explanations have been offered 
over many years, a collectively clearer answer may be possible.   
 
3.3  Detection of HIV-1 cDNA 
The recently discovered cytoplasmic DNA sensor, cGAS, has become a 
prominent candidate for HIV-1 sensing.  Viral cDNA, produced following reverse 
transcription, may be open to detection before it enters the nucleus and 
undergoes genomic integration.  Indeed, studies have reported cGAS mediated 
innate activation of both DCs and macrophages.   In most cases, Vpx addition 
through the use of SIV viral like particles was used to promote reverse 
transcription thereby leading to the production, and assumed accumulation, of 
cytoplasmic HIV-1 cDNA.  In several cases, this was sufficient by itself to induce 
a type 1 interferon response in macrophages and DCs (Chen et al., 2016; Gao et 
al., 2013; Wu et al., 2013; Yoh et al., 2015).  In other reports, HIV-1 has been 
shown to circumvent cGAS detection in DCs and macrophages regardless of Vpx 
addition. This restriction to detection of viral cDNA was alleviated with mutations 
to the viral capsid to change the affinity for CypA and CPSF6 (Lahaye et al., 
2013; Rasaiyaah et al., 2013).  Protected by the viral capsid, reverse 
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transcription takes place ostensibly protected from cytoplasmic sensors like 
cGAS until nuclear import and integration.   
Detection of HIV-1 cDNA would logically be a process independent of viral 
integration.  It stands to reason that nuclear import and chromosomal integration 
of viral cDNA would negate its capacity to be detected by cytoplasmic DNA 
sensors.  In seeming conflict with this rationale, CD4+ T cells were reported to 
induce type 1 interferon following HIV-1 infection in a manner dependent on both 
cGAS sensing of viral cDNA and proviral integration and expression (Vermeire et 
al., 2016).  Disruption of the cGAS signaling axis abrogated innate activation 
leading the authors to suggest an elaborate model of HIV-1 detection involving 
cGAS detection determinants both before and after integration.  A mechanism for 
this detection is unknown and was not described in cells other than T cells 
(Vermeire et al., 2016).   
While these observations appear incongruous, a recent report may provide a 
degree of corroboration.  In partial agreement with the aforementioned study, 
Vpx assisted HIV-1 infection of DCs was shown to induce maturation involving 
steps both before and after viral integration (Johnson et al., 2018).  Immediately 
following HIV-1 challenge, a low level interferon response was detected that was 
unaffected by inhibition of integration. This low level response was found to be 
mediated by the cGAS signaling pathway.  However, robust DC maturation, as 
evident by a much stronger type 1 interferon response and upregulation of 
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costimulatory CD86, was only found following integration and expression.  This 
secondary amplification of the antiviral response required both the initial cGAS 
“priming” response and subsequent activation of NF-κB.  While it is unknown by 
what mechanism HIV-1 transcription is sensed or how NF-κB is recruited, the 
concept of a multiple sensing mechanisms with determinants both before and 
after integration may offer an explanation to seemingly conflicting observations.   
 
3.4  Detection of HIV-1 RNA processing 
Naked HIV-1 RNA sequences and structures have been shown to be substrates 
for cytoplasmic RNA receptors like RIG-I (Berg et al., 2012; Solis et al., 2011).  
The proposed mechanism in these studies argue for the detection of incoming 
HIV-1 genomic RNA prior to reverse transcription and subsequent RNAse H 
degradation.  However, these studies mainly utilized transfections of genomic 
HIV-1 RNA or HIV-1 RNA motifs as opposed to genuine HIV-1 challenge.  In 
addition to the questionable relevance of transfected RNAs, this methodology 
would be unable to distinguish whether de novo HIV-1 RNAs, as opposed to 
incoming virion associated genomic RNA, could be detected.  In contrast, one 
study has described an integration dependent mechanism in which newly 
transcribed HIV-1 RNA is sensed by the host helicase DDX3 (Gringhuis et al., 
2016).  Transfection studies in DCs implicated short, abortive HIV-1 RNA 
products to be determinants for interferon production through the direct binding of 
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DDX3 and signaling through MAVS.  However, it is unknown whether abortive 
transcription products constitute the determinant for detection in primary viral 
infection.   
Interestingly, DDX3 has also been shown to be a contributing factor for the Rev-
CRM1 mediated export of intron containing HIV-1 RNAs (Mahboobi et al., 2015; 
Valiente-Echeverría et al., 2015; Yedavalli and Jeang, 2011; Yedavalli et al., 
2004).  In addition, DDX3 acts to promote HIV-1 translation initiation by binding 
directly to the TAR stem loop structure as a substitute for eIF4E mRNA 5’ cap 
binding (Lai et al., 2013; Liu et al., 2011; Soto-Rifo et al., 2013).  As such, it is 
apparent that DDX3 binds to de novo transcribed genomic HIV-1 RNA following 
integration to both promote its export and its translation.   
In two simultaneous studies, DCs, macrophages, and CD4+ T cells were all 
shown to induce an antiviral response upon HIV-1 challenge (Akiyama et al., 
2017; McCauley et al., 2017).  Similarly to the preceding studies, this innate 
activation was dependent on integration and expression of the provirus.  
However, the authors found no specific viral sequence determinants nor a 
connection or reliance on cGAS-STING-IRF3 signaling.  Innate activation was 
shown to be entirely dependent on Rev mediated export of unspliced and 
partially spliced HIV-1 RNA through the CRM1 RNA export pathway.  
Furthermore, transduction of the virus could be separated from RNA transcription 
for at least 9 days suggesting that RNA export detection is independent of any 
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steps prior to integration as well as the process of integration itself.  The authors 
conclude that, as long as Rev-CRM1 export of the RNA is still maintained, a 
provirus need not be intact or replication competent to induce innate activation 
(Akiyama et al., 2017; McCauley et al., 2017).  The outstanding question is how 
HIV-1 unspliced RNA export itself is detected; whether it is by escape of 
unspliced RNA, the overt use of the CRM1 pathways itself, binding of cellular 
signaling determinants such as RIG-I or DDX3, or some combination thereof.   
 
3.5  Putting the pieces together   
Disagreement exists over whether cGAS is responsible for post-integration 
signaling or if it is limited to detection of viral DNA before integration.  HIV-1 
infection of CD4+ T cells has been shown to induce type 1 interferon in a 
mechanism dependent on cGAS signaling and on proviral production (Vermeire 
et al., 2016).  Considering reverse transcribed HIV-1 cDNA would theoretically 
only be available to detection prior to nuclear import and chromosomal insertion, 
it is difficult to conjecture a mechanism by which cGAS detects viral DNA 
following integration.  The authors suggest that, rather than incoming viral cDNA, 
cGAS might detect released mitochondrial DNA as due to stress from viral 
production or viral cDNA from other simultaneous infection events.  However, this 
mechanism has not been identified nor has it been observed in other cell types.   
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Other studies have found that HIV-1 integration and subsequent expression are 
necessary and sufficient to activate DCs without apparent cGAS signaling.  
Detection of de novo transcribed HIV-1 RNA in DCs is a process that inherently 
occurs subsequently to viral integration.  An important exception is that of limited 
transcription from transient, unintegrated HIV-1 DNA circles (Brussel and Sonigo, 
2004; Kelly et al., 2008; Sloan et al., 2010; Thierry et al., 2016; Wu and Marsh, 
2003).  However, this seems unlikely, as experimental inhibition of integration 
does not inhibit accumulation of unintegrated DNA, and hence, it’s transcription 
(Munir et al., 2013).   
In partial agreement with the aforementioned, post integration sensing of HIV-1 
RNA has been shown in two accompanying studies to occur in DCs, 
macrophages, and CD4+ T cells (Akiyama et al., 2017; McCauley et al., 2017).  
Innate activation required both proviral integration and expression and was 
exclusive of the cGAS-STING-IRF3 signaling axis.  It was further found that 
induction of type 1 interferon was contingent on Rev-CRM1 RNA export of intron 
containing HIV-1 RNA.  In addition, this response was separable from HIV-1 
transduction by at least nine days suggesting a plenary independence of pre-
integration sensing events (McCauley et al., 2017).  While it is unresolved to 
what adaptor or mechanism links HIV-1 incompletely spliced RNA export to 
induction of type 1 interferon, it remains plausible evidence of post integration, 
cGAS independent sensing.   
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As alluded to prior, cellular detection of pre-integrated HIV-1 cDNA by cGAS or of 
post integration transcription may not be mutually exclusive mechanisms.  A 
recent effort has proposed that both may occur either independently or as 
multiple steps in a connected mechanism (Johnson et al., 2018).  In this study, 
microarray and ATAC-seq analysis on HIV-1 infection of Vpx treated DCs clearly 
demonstrate two stages of innate activation.  The first manifests as a low level 
interferon response immediately following infection, unaffected by inhibition of 
integration.  In contrast, a far more potent interferon and maturation response 
was observed not until two days following HIV-1 challenge.  Similarly to the 
aforementioned studies, this robust secondary response was found to require 
both integration and transcription of the provirus.  Knockdowns in DCs and 
CRISPR knockouts in THP1 derived DC-like cells suggested that the early, 
limited interferon response was mediated by cGAS-STING-IRF3 signaling.  In 
addition, this secondary amplification was shown to require both the initial cGAS 
dependent response and the subsequent activation of NF-κB by an unknown 
mechanism.  These observations led the authors to offer a model in which pre-
integration cGAS sensing of HIV-1 cDNA induces a “priming” response that is 
further amplified by NF-κB activation following HIV-1 transcription.   
It would seem likely that this strong, successive interferon induction seen in HIV-
1 infected DCs is the same response described in Akiyama et al. and McCauley 
et al. to sense incompletely spliced HIV-1 RNA export.  Both proposed 
mechanisms are dependent on integration and subsequent transcription of the 
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provirus.  Each was characterized by a potent type 1 interferon response delayed 
significantly following transduction with peak response two days post HIV-1 
challenge.  Nonetheless, knockdowns and drug inhibitors of cGAS-STING-IRF3 
signaling failed to abolish interferon induction and DC maturation (Akiyama et al., 
2017; McCauley et al., 2017).  This is in contrast to the two stage sensing 
hypothesis by Johnson et al., in which cGAS sensing was proposed to “prime” a 
pro-antiviral state that is later amplified by viral replication.  Interestingly, careful 
analysis of my work in the preceding chapter (as well as McCauley et al.) does 
indicate that inhibition of integration by integrase mutation or raltegravir did not 
fully abolish ISG induction.  Indeed, integration deficient samples yielded 100 fold 
higher CXCL10 RNA over background (McCauley et al., 2017).  However, as 
inhibition of integration resulted in 1000 fold less CXCL10 RNA expression and 
abrogation of surface CD86 as compared to unhindered HIV-1 infection, this 
observation was not further investigated.  Nonetheless, it is plausible that the 
significantly reduced ISG induction observed upon integration inhibition may 
reflect early, cGAS mediated innate activation.  
 
3.6  Outstanding questions and speculations 
The theory that best connects and explains the various observations presented is 
that of a two stage response to HIV-1 infection of dendritic cells.  The initial 
response is that of a low level type 1 interferon induction that occurs prior to 
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integration and is dependent on HIV-1 cDNA detection by cGAS and subsequent 
signaling through STING and IRF3.  The second response is characterized by a 
far larger induction of interferon and ISGs and is dependent on viral integration, 
transcription, and Rev-CRM1, HIV-1 RNA export.  While this serves to identify 
the causative factor necessary for innate activation, it still leaves several 
unanswered questions.   
It is also not known whether other dendritic cell subtypes react similarly to 
monocyte derived dendritic cells and macrophages.  Monocyte differentiated 
cells are, by far, the most common experimental model for dendritic cell and 
macrophage biology.  This is mainly due to the fact that dendritic cells are 
extremely heterogeneous and exist in fleeting numbers in vivo.  Isolation and 
differentiation of CD14+ monocytes limits the variability between donors and 
greatly increases the total cell yield.  As a result, data on the infection of proper 
dendritic cells both in vivo and ex vivo is limited (Ahmed et al., 2015; Granelli-
Piperno et al., 2006).  Interestingly, it has been found that ex vivo isolated 
myeloid and plasmacytoid dendritic cells are even more resistant to HIV-1 
transduction than monocyte derived cells (Bloch et al., 2014).  It was found that 
the levels of cellular SAMHD1 were much higher in ex vivo myeloid dendritic cells 
and that Vpx was insufficient to alleviate the block to reverse transcription.  
However, the term myeloid dendritic cell encompasses multiple cell subtypes 
more classically referred to as common dendritic cells.  Different myeloid 
dendritic cell subtypes have widely varying functions, interactions, and tissue 
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locations.  As such, the development of effective immunotherapies will 
necessitate a better understanding of how individual dendritic cell subtypes react 
to HIV-1 challenge.   
As mentioned before, the delayed but robust interferon and maturation response 
seen in HIV-1 infected DCs may or may not be dependent on early cGAS 
signaling.  In more molecular terms, is the export of unspliced HIV-1 RNA via 
CRM1 sufficient to induce dendritic cell maturation or is a prior stimulus needed 
to induce a state of heightened sensitivity?  In some cases, suppression of cGAS 
signaling appears to prevent downstream, integration dependent innate 
activation (Johnson et al., 2018; Vermeire et al., 2016).  In other cases, cGAS 
sensing appears to be dispensable for a potent immune response (Akiyama et 
al., 2017; Gringhuis et al., 2016; McCauley et al., 2017; Nasr et al., 2017).  It has 
been suggested that, if a priming response is required, another stimulus may be 
able to functionally substitute for cGAS detection (Johnson et al., 2018).  
Furthermore, addition of a secondary stimulus following integration deficient HIV-
1 infection was shown to dramatically increase the resultant activation state to a 
degree similar to that of unhindered infection.   
Technical limitations limit experimental design: how does one isolate post-
integration sensing events from pre-integration ones?  This question was partly 
addressed through our use of a doxycycline inducible, Tat independent HIV-1 
construct (McCauley et al., 2017).  By transducing monocytes with Tet-HIV-1 
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immediately following isolation, the process of reverse transcription and 
integration occurs during the differentiation of the dendritic cells without 
immediate transcription.  With this technique, viral challenge was separated from 
transcription initiation by 9 days in dendritic cells and CD4+ T cells with innate 
activation directly correlating with doxycycline concentration (McCauley et al., 
2017).  This would suggest that the detection of HIV-1 RNA export is sufficient to 
induce activation sans prior stimulation from cGAS or otherwise.  It is important 
to note that a prior stimulation may induce permanent epigenetic and 
transcriptional changes separable by no length of time.  However, this would 
seem unlikely considering that the cells are transduced as monocytes and must 
undergo large scale epigenetic and transcriptional changes just to differentiate.   
The most significant unknown is the mechanism linking CRM1 export of 
unspliced HIV-1 RNA to innate signaling and interferon activation.  Continued 
genetic experimentation on the HIV-1 genome will likely determine whether or not 
the sequence of the Env intron is necessary for innate detection.  It is possible 
that the overt or improper use of the CRM1 export pathway sufficient is sufficient 
to induce activation without direct sequence specificity.  Indeed, CRM1 RNA 
export is a highly specific pathway necessitating the use of secondary proteins to 
directly bind to RNA and bridge transport (Delaleau and Borden, 2015; Okamura 
et al., 2015).  In HIV-1, this role is fulfilled by the Rev protein.  However, CRM1 is 
primarily a protein transporter for complexes containing canonical nuclear export 
signals and commonly exports highly diverse cargos.  As such, it is difficult to 
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imagine a mechanism by which use of the CRM1 pathway itself would activate 
immune signaling.   
A more likely scenario is one where HIV-1 RNA acts as the direct determinant for 
the innate sensing.  In this scenario, the genomic HIV-1 RNA, inclusive of the 
Env intron, is the substrate for direct or indirect innate detection.  It is possible 
that interactions occur directly with a known signaling adapter or recognition 
receptor; however, this reasoning would not serve to explain the necessity for 
CRM1 export.  Another possibility is that sequence specific interactions with HIV-
1 RNA co-export proteins not normally found outside the nucleus.  Perhaps these 
are proteins that are regularly removed from RNAs during NXF1/TAP mRNA 
export but are retained when exported via CRM1.  Once in the cytoplasm, these 
mislocalized proteins might be recognized as a danger signal leading to 
interferon activation.  
The HIV-1 RNA is itself known to associate with a diverse array of proteins 
(Knoener et al., 2017; Kula et al., 2011; Marchand et al., 2011; Milev et al., 2012; 
Naji et al., 2012).  Moreover, intron containing HIV-1 RNA is known to associate 
with many unique proteins not found with its accompanying spliced RNAs (Kula 
et al., 2011; Naji et al., 2012).  These include RNA helicases, splicing regulators, 
HNRNPs, and DNA damage associated proteins among many others.  Of note, 
Rev exported HIV-1 RNA binds multiple RNA helicases of the DEAD/H box 
protein family including DDX1, DDX3, DDX5, DDX7, DHX9, DDX17, DDX21, and 
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DDX24.  Furthermore, DDX1 (Edgcomb et al., 2012; Fang et al., 2004), DDX3 
(Yedavalli et al., 2004), DDX5 (Zhou et al., 2013), DHX9 (Bolinger et al., 2010) 
DDX17 (Lorgeoux et al., 2013; Sithole et al., 2018), and DDX24 (Ma et al., 2008) 
have all been shown to have widely varying effects on HIV-1 replication; some 
positive and some negative.  Many of these helicases also have known functions 
in various innate processes such as direct detection of nucleic acids, adapters for 
signaling, and regulation of viral replication (Cheng et al., 2018; Fullam and 
Schröder, 2013; Ma et al., 2013; Rahman et al., 2017; Sekiba et al., 2018; Shan 
et al., 2012; Valiente-Echeverría et al., 2015; Xu et al., 2010; Zhang et al., 2011).   
In fact, DDX3 has been implicated in the direct sensing of transcribed HIV-1 RNA 
in an integration dependent manner (Gringhuis et al., 2016).  Although the 
authors implicate abortive, Tat independent transcription, as opposed to CMR1 
exported RNA, as the determinants for activation, it still serves to illustrate the 
potential for DDX mediated detection.  As such, it is not difficult to imagine that 
an RNA helicase could act as a direct recognition receptor for HIV-1 RNA.  This 
hypothetical binding factor would then escape the nucleus by co-transporting with 
the unspliced HIV-1 genome via CRM1 and induce innate activation once 
recognized in the cytoplasm.   
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3.7  Experimental considerations 
While the focus of this text has been on innate detection of HIV-1 in dendritic 
cells, the research cited and discussed was performed in a variety of cell types 
including whole PBMCs, CD4+ T cells, and macrophages, as well as numerous 
cell lines.  It serves to reason that any number of observations made may not be 
relevant outside the cited system.  It very well may be that different cell types 
react differently to HIV-1 infection.  Indeed, plasmacytoid DCs have been shown, 
without experimental assistance, to readily sense HIV-1 through detection of 
incoming viral RNA via TLR7 (Beignon et al., 2005; Fonteneau et al., 2004; 
Haupt et al., 2008; Lepelley et al., 2011; Smed-Sörensen et al., 2005).  However, 
the lack of TLR7 (and downstream IRF7) expression in myeloid, or common, 
dendritic cells prevents this route of innate activation (Bloch et al., 2014; Izaguirre 
et al., 2003; Jarrossay et al., 2001; Wacleche et al., 2018).  In addition, even 
when observations are made in the same or similar cell types, eg. DCs and 
macrophages, differences in cell culturing, viral production, and assay conditions 
can drastically change the experimental outcome.   
Difficulties determining the dependence for cGAS detection of HIV-1 infection in 
DCs may also stem from differences in reagent and assay conditions.  In most 
studies, HIV-1 virus is produced via transfection of 293 cells and is harvested 
days later as virally enriched supernatant.  In addition to virus, this media may 
also contain stimulating byproducts of cellular metabolism as well as leftover 
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transfection reagents and DNA.  HIV-1 preparations themselves are 
amalgamations of functional viral particles mixed with other products contained 
within cell treated supernatants.  Even purportedly purified viral particles are 
either precipitated out of solution with other exosomes or centrifuged on a 
sucrose gradient that would not exclude similarly dense vesicles.   
Dendritic cells are a highly heterogeneous cell type with numerous subtypes with 
classifications dependent on in vivo localization, marker expression, and T cell 
presentation capacity (Kaisho, 2012; Liu, 2001; Palucka and Banchereau, 2013; 
Piguet and Blauvelt, 2002; Piguet and Steinman, 2007; Schreibelt et al., 2010; 
See et al., 2017; Villani et al., 2017; Wacleche et al., 2018).  Furthermore, the 
majority of dendritic cell reports utilize monocyte derived dendritic cells (mdDC) 
as these can be produced reliably and in larger quantities than DCs isolated ex 
vivo.  These are a cell type differentiated from monocytes in vitro by culturing in 
the presence of GM-CSF and IL4.  Originally considered to be a culturing oddity 
with questionable disease relevance, mdDCs have been shown to be a true DC 
subset that differentiate in vivo during inflammation (León and Ardavín, 2008; 
León et al., 2007; Nakano et al., 2009; Wacleche et al., 2018).  The specific 
culturing conditions can dramatically alter the phenotype of DCs and 
macrophages differentiated from monocytes in vitro (Qu et al., 2014; Safi et al., 
2016; Wacleche et al., 2018).  For example, during differentiation of 
macrophages from monocytes, the use of fetal bovine serum induces a transition 
to a G1 state as compared to a G0 state from when human serum is used.  
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Moreover, this G1 state induces the phosphorylation of SAMHD1 thereby 
reducing its capacity to restrict HIV-1 reverse transcription (Mlcochova et al., 
2017; Moldenhauer et al., 2003).  This greatly increases the permissivity to HIV-1 
infection without the use of Vpx protein to degrade SAMHD1, which, as 
discussed, may or may not be a limiting factor in cGAS detection of reverse 
transcribed HIV-1 cDNA.   
Dendritic cells are immune cells possessing a complex collection of sensors 
specific to a diverse array of host and pathogenic molecules.  As such, they are 
highly sensitive to differences in experimental conditions and will alter their 
behavior in unknown ways.  It is entirely possible that differences in culturing 
conditions can cause monocytes to differentiate along subtly disparate DC 
lineages that react opposingly to HIV-1 infection.  Indeed, unpublished 
observations indicate that mdDCs differentiated in the presence of fetal bovine 
serum express a different surface marker profile than those in human serum.  
FBS derived mdDCs express a profile of CD1a+, CD1c++, CD11c+, CD14-, DC-
SIGN+, as well as HLA-DR++, CD80+, CD83++, and CD86+ upon stimulation.  
Human serum derived mdDCs express a similar repertoire with minor differences 
including: CD1a+/-, CD1c++, CD11c+, CD14+, DC-SIGN+ and, upon stimulation, 
express HLA-DR+, CD80+, CD83+, and CD86++.  Interestingly, recent studies of 
single cell RNA sequencing on ex vivo isolated monocytes and DCs report 
similar expression profiles in CD1c+ DC subsets (See et al., 2017; Villani et al., 
2017).  Villani et al describes two, closely related, but distinct, DC subsets in the 
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classical CD1c+ DC lineage.  Comparison of expression profiles would suggest 
that FBS derived mdDCs maintain similarity to “CD1c_A” DCs whereas human 
serum derived DCs appear closer to “CD1c_B” DCs.  Both DC subsets were 
shown to be potent stimulators of naive T cell expansion and to react similarly to 
LPS, poly(I:C), and R848 (Villani et al., 2017).   
It is entirely possible that different DC subsets, regardless of similarity, may react 
opposingly to HIV-1 infection and could account for disparities observed in 
separate studies.  Johnson et al. described a “priming” response potentiated by 
cGAS detection of pre-integrated HIV-1 cDNA that led to a chromatin state 
permissive to downstream, post integration DC maturation.  Perhaps the 
necessity for prior epigenetic priming is dissimilar between different DC subtypes 
or other cell types like macrophages and T cells.  A better understanding of the 
functional differences of in vivo DC lineages will be essential to determining 
exactly how HIV-1 interacts with the innate immune system on a functional level.  
Furthermore, advances in genetic and expression manipulation will allow for the 
elucidation of the dependence of particular sensors and signaling pathways to 
the HIV-1 response.  From there, it may be possible to manipulate the response 
to induce a protective and permanent anti-HIV-1 immune response. 
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